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ABSTRACT 
 
Convergence of pathways in motoneuron (MN) injury include microglia in the initiation and 
progression of Amyotrophic Lateral Sclerosis (ALS). Neuroinflammation is a pathological hallmark of 
ALS and microglia may acquire neurotoxic or neuroprotective properties in response to misfolded 
superoxide dismutase-1 (SOD1) or other molecules produced by the injured MN. 
We assessed: (i) the role of microglia in preventing/restoring MN dysfunction using a mixed 
culture of NSC-34 MN-like cells (mutated in G93A) and of N9 microglia cells,  added at 0 or 2 days-in-
vitro (M0, M2) and cultured till 4 and 7 days-in-vitro; (ii) neurodegenerative network in organotypic 
cultures from lumbar segments of spinal cord (SC) obtained from the ALS mice model TgSOD1-G93A 
at 7 day-old and aged for 10 days-in-vitro, as well as the response to lipopolysaccharide (LPS, 1 
μg/mL) immunostimulation. Western blot assays for SOD1, high-mobility-group-box-protein-1 
(HMGB1) and toll-like receptor-4 (TLR-4), and fluorimetric/colorimetric assays for ATP, glutamate and 
nitric oxide (NO), were used. 
Microglia (M0/M2) decreased the accumulation of human/mouse mutated SOD1 (P<0.01). In 
addition, elevation of glutamate efflux (P<0.01), and reduction of extracellular ATP (P<0.01), MMP-2 
(P<0.05) and MMP-9 (P<0.01) was observed by M2 at 7 days-in-vitro. Reduction of NO (P<0.05) and 
MMP-2 (P<0.01) was obtained with M0. HMGB1 increased by M0 and decreased by M2, suggesting 
HMGB1 release from the cell. Accumulation of SOD1 was verified in SC organotypic cultures, but no 
changes in ATP or NO were obtained, although a slight decrease in ATP by LPS was verified. Down-
regulation of TLR-4 by LPS may indicate the exhaustion of the inflammatory response mechanisms in 
the aged SC culture. 
Together, these results suggest that microglia by inhibiting MMP activation and HMGB1 
cytoplasmic translocation in the ALS model are key in modulating MN degeneration and should be 
considered as therapeutic targets in ALS. 
 
 
 
Keywords: Inflammatory mediators; Microglia modulatory effects of motoneuron 
degeneration; microglia-motoneuron communication; neuroinflammation; SOD1 accumulation 
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RESUMO 
 
A convergência das vias de sinalização envolvidas na lesão dos neurónios motores (NM) 
inclui a microglia no início e progressão da Esclerose Lateral Amiotrófica (ELA). A neuroinflamação é 
uma característica da ELA e a microglia pode adquirir propriedades neurotóxicas ou neuroprotectoras 
em resposta ao misfolding da superóxido dismutase 1 (SOD1) ou a outras moléculas produzidas 
pelos MNs lesados. 
Avaliou-se: (i) o papel da microglia na prevenção/reparação da função dos NM usando uma 
cultura mista de NSC-34 MN-like cells (mutada em G93A) e células microgliais N9, adicionadas aos 0 
e 2 dias de diferenciação  (M0, M2) e cultivadas 4 e 7 dias-in-vitro; (ii) a neurodegenerescência de 
culturas organotípicas de segmentos lombares da medula espinhal (ME) de murganhos transgénicos 
TgSOD1-G93A obtidas aos 7 dias de vida, envelhecidas durante 10 dias-in-vitro, e a resposta ao 
lipopolisacárido (LPS, 1 μg/mL).  Utilizou-se o Western blot para a SOD1, high-mobility-group-box-
protein-1 (HMGB1) e toll-like receptor-4 (TLR-4), bem como ensaios fluorimétricos/colorimétricos para 
ATP, glutamato e óxido nítrico (NO). 
A microglia (M0/M2) diminuiu a acumulação de SOD1 mutada (P<0.01). Verificou-se haver 
aumento da libertação de glutamato (P<0.01) e redução de ATP (P<0.01), MMP-2 (P<0.05) e MMP-9 
(P<0.01) no meio extracelular pela M2 aos 7 dias-in-vitro. Igualmente se obteve diminuição de NO 
(P<0.05) e MMP-2 (P<0.01) com M0. O HMGB1 aumentou pela M0 e diminuiu pela M2, indicando a 
sua libertação pela célula. Verificou-se a acumulação de SOD1 nas culturas organotípicas, mas sem 
alteração de ATP ou NO, apesar do LPS ter causado um pequeno decréscimo do ATP. A inibição do 
TLR-4 pelo LPS sugere o colapso dos mecanismos de resposta inflamatória na cultura.   
Os resultados ao evidenciarem a inibição da activação das MMP e da translocação 
citoplasmática do HMGB1 pela microglia no modelo de ELA apontam-na como alvo terapêutico na 
modulação da neurodegenerescência dos NM na ALS. 
 
 
 
Palavras-chave: Mediadores inflamatórios; efeitos moduladores exercidos pela microglia na 
degeneração dos neurónios motores, comunicação entre os neurónios motores e a microglia; 
neuroinflamação; acumulação de SOD1 
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I. INTRODUCTION 
 
 
 
1. New insights on amyotrophic lateral sclerosis (ALS) 
Amyotrophic Lateral Sclerosis (ALS), also known as Charcot’s disease or as Lou Gehrig’s 
disease (Naganska and Matyja, 2011) is a neurodegenerative disease characterized by death of lower 
motoneurons (MN) in the brainstem and spinal cord (SC) and of upper MN in the motor cortex 
(Ferraiuolo et al., 2011), as showed in Figure I.1. The name “amyotrophic” are related to the atrophy of 
muscle fibers, weakness and loss of muscle mass; “lateral” refers to the nerve pathways that are 
localized along both sides of the SC, and “sclerosis” is the scan tissue resulted from the process of 
nerve degeneration. ALS was first described by Jean- Marie Charcot in 1869, a French neurobiologist 
and physician who associated most of the symptoms with the lesion of MN  that originate in the SC 
(Musaro, 2010). Some groups of neurons such as the ones in upper brainstem nuclei (that control eye 
movements) and neurons in Onuf’s nucleus within the sacral SC (that control the bladder) are less 
affected by this disease (Kirby et al., 2005). Despite the cognitive ability, sensation and autonomic 
nervous functions are usually not affected, 5-10% of patients with ALS also develop fronto-temporal 
lobar dementia (Redler and Dokholyan, 2012). Clinical presentation includes weakness, wasting, 
fasciculations and atrophy of muscles involving the bulbar and limb regions. ALS leads to a slurred 
speech, dysarthria, a progressive paralysis and ultimately death, usually by respiratory failure (Kiernan 
et al., 2011; Musaro, 2010; Shaw, 2005). 
If the disease affects only the spinal lower MNs, the condition is called “progressive muscular 
atrophy”; if only the upper MNs are affected, the condition is called “primary lateral sclerosis”; finally, if 
only the bulbar musculature is affected, the denomination is “progressive bulbar palsy”. Most of the 
patients with at least one of these initial conditions will develop features of ALS over time (Shaw, 
2005).  On the other hand, some long-term survivors maintain one of those variants of ALS (Evans et 
al., 2013). Moreover, these variants differ from ALS in terms of disease progression, survival and 
clinical presentation; in progressive muscular atrophy the prognosis is better, with a 5-10 year of 
survival rate, slow progression and absence of upper MN signs (brisk reflexes, spastic catch and 
Babinski sign) (Kim et al., 2009). Although primary lateral sclerosis has many similarities with ALS, 
disease progression is slower, survival is longer and patients usually show muscle stiffness or 
spasticity and, very rarely, limb wasting (Tartaglia et al., 2007). Progressive bulbar palsy tends to have 
a worse prognosis than ALS and the other variants, and involves death of MN of the lower brainstem 
with or without involvement of the cortico-bulbar tract (Karam et al., 2010). 
The worldwide prevalence is 3-5/100,000 habitants and the lifetime risk of developing ALS is 
1-800 (Naganska and Matyja, 2011; Redler and Dokholyan, 2012). Usually, ALS first symptoms occur 
at middle age (50-60 years), although it may appear in younger people, with an incidence of 1-3/500 
000(Ferraiuolo et al., 2011; Kirby et al.,2005; Naganska and Matyja, 2011). It generally affects more 
men than women, with a male to female ratio of approximately 1.6/1. The average survival is 3 years 
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from symptoms onset but a small proportion of patients have a slower disease course (Wood-Allum 
and Shaw, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.1 - Amyotrophic Lateral Sclerosis is a neurodegenerative disease characterized by death of lower 
motoneurons (LMN) in the brainstem and spinal cord and of upper motoneurons (UMN) in the motor 
cortex. UMN connect motor cortex and spinal cord, through the extension of their fibers along the brainstem, 
while LMN connect spinal cord to voluntary muscles. Together, they form the corticospinal tract. A fail in one of 
these connections originates weakness, wasting, fasciculations and muscle atrophy involving the bulbar and limb 
regions. Consequently, it leads to a slurred speech, dysarthria, progressive paralysis and ultimately death, usually 
by respiratory failure. 
 
1.1. Genetic Causes 
It has been proposed a large genetic contribution for ALS, once it was observed that Mendelian 
genes are mutated in individuals with no familial history of this disease (Al-Chalabi and Lewis, 2011). 
However, it is difficult to identify ALS genes because it is a disease of later life, so it is rare to obtain 
large pedigrees for linkage studies, and the prognosis is poor, making the point prevalence 
consequently low (Al-Chalabi et al., 2012). Nevertheless, about 90-95% of ALS cases are classified as 
sporadic (sporadic ALS or sALS), with unknown causes, and 5-10% of cases are inherited (familiar 
ALS or fALS). The most common inheritance pattern for fALS is autosomal dominant (Naganska and 
Matyja, 2011). Several genes have been identified as a cause or risk factor for the development of the 
disease (Armon, 2005), revealing a high degree of heterogeneity (Sabatelli et al., 2013). That 
identification has provided important clues about the molecular mechanisms implicated in ALS 
(Naganska and Matyja, 2011). Among these genes, it stands out the gene encoding superoxide 
dismutase 1 (SOD1), which accounts up to 20% of inherited ALS cases (Andersen, 2006), TAR DNA 
binding protein/TDP-43 (TARDP) (Sreedharan et al., 2008) and mutations in the fused in 
sarcoma/translated in liposarcoma (FUS/TLS) (Kwiatkowski et al., 2009). 
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1.1.1 Mutations in SOD1 
The discovery in 1993, by Rosen and collaborators, of the mutations in the gene on 
chromosome 21q22.1, which encodes the enzyme superoxide dismutase 1 (SOD1), marked the 
beginning of the research around the causes of ALS (Rosen et al., 1993). 
These mutations account for 20% of fALS cases (Rowland and Shneider, 2001), although the 
frequency varies among populations (Andersen, 2006). The patients with mutant SOD1-related ALS 
show several phenotypes, but the typical fast progressive ALS phenotype prevails and is clinically not 
distinguishable from sALS (Ince et al., 2011). 
SOD1 is a metalloenzyme that acts as a homodimer and whose function is to convert 
intracellular superoxide free radicals – a toxic waste product of mitochondrial oxidative 
phosphorylation – to hydrogen peroxide (H2O2). Subsequently, the H2O2 is eliminated by the action of 
other free radical scavenging enzymes (Siegel et al., 2006). The elimination of radicals protects the 
cell from deoxyribonucleic acid (DNA) and intracellular protein oxidative damage (Naganska and 
Matyja, 2011). SOD1 contains one cooper and one zinc ion per monomer. The cooper ion has an 
active scavenging activity (Bendotti et al., 2012), while the zinc ion stabilizes the protein structure 
(Shaw, 2005). This protein is widely expressed in the mammalian central nervous system (CNS), 
accounts for about 1% of all brain proteins and is present at a very high content in MN (Siegel et al., 
2006). 
It has been identified more than 160 mutations so far, spanning all five exons (Sabatelli et al., 
2013). Most of the mutations are missense, which most probably alter the active site of the enzyme 
(Shaw and Eggett, 2000), while non-sense mutations or gene deletions are rare. Most of the mutations 
are inherited in an autosomal dominant form (Sabatelli et al., 2013); the mutation resulting from  
substitution of alanine by valine in position 5 of the protein (p.ALA5VAL) is present in 50% of families 
in USA, and is usually associated with a fast progressive disease (Al-Chalabi et al., 2012). 
Initially, there were findings suggesting a loss of SOD1 function as a causative mechanism of ALS, 
due to the decrease of the enzymatic activity in patients with ALS, and the distribution of ALS-
causative mutations spread throughout the SOD1 gene (Deng et al., 1993; Rosen et al., 1993). 
Further studies evidenced that mutated SOD1 (mSOD1) possesses a neurotoxic property that is 
responsible for the pathogenic mechanisms of the disease and known as gain of function hypothesis. 
It began with the analysis of mSOD1 mouse models by Gurney and colleagues (1994). Actually, there 
are more than 12 different published human mSOD1 transgenic (tg) strains, which contribute to the 
development of a progressive adult-onset motor phenotype, characterized by the loss of lower MN 
(Joyce et al., 2011). Although the two hypothesis are still discussed, there is increased evidence that 
the gain of function hypothesis is most likely because: a) in humans no correlation was found between 
SOD1 dismutase activity and severity of clinical phenotypes (Ratovitski et al., 1999); b) in mice, no 
evidence of ALS-like phenotype was found in SOD1 null animals (Reaume et al., 1996); and c) Bruijn 
and colleagues (1998) found no change in survival time of mice carrying a mSOD1 transgene (SOD1 
G85R) on a normal mouse background (i.e. with two copies of the endogenous mouse Sod1 gene) 
compared with the same transgene on a null SOD1 background. 
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It has been investigated the correlation between mutations and phenotype due to the large 
vulnerability of phenotypes in terms of disease progression, extramotor features and age of onset 
(Milani et al., 2011).The heterogeneity among SOD1 mutation is responsible for a difficult identification 
of pathways that leads to the cell death of MN (Bruijn et al., 2004).  
 
1.1.2 - Mutations in TDP-43 and FUS  
Both TDP-43 and FUS/TLS are multifunctional proteins with functions related to gene 
expression, transcription, RNA splicing, transport and translation. They are also responsible for the 
processing of microRNAs (miRNAs), RNA maturation and splicing (Kiernan et al., 2011). Mutations in 
TDP-43 and FUS account for 4-5% of patients with fALS (Naganska and Matyja, 2011) and 5 % of 
sALS, in the case of TDP-43 (Redler and Dokholyan, 2012). It was found an association between ALS 
with frontotemporal dementia (FTD) and Parkinsonism in patients with chromosome 17-linked disease 
with mutations in the TDP-43. ALS with dementia also occurs in the gene mapped to 9q21-22 
(Rowland and Shneider, 2001). The inclusions are present in half patients with FTD (Neumann et al., 
2006). In addition, mutations in FUS gene were found in patients with FTD and fALS with Parkinson’s 
disease (Yan et al., 2010). 
Regarding TDP-43, mutations in this gene results in a neuronal aggregation of abnormal 
protein in patients with sALS and non-SOD1 fALS (Tan et al., 2007). This mislocalization within the 
cell is responsible for the toxicity in MN, but how TPD-43 causes the disease is still unknown (Traub et 
al., 2011). Besides studies of patients with TARDP mutations, a tg mice expressing the mutated 
human TDP-43 developed by Wegorzewska and colleagues (2009) causes a clinical syndrome similar 
to human ALS, but without cytoplasmatic aggregates of TDP-43. Zhou and colleagues (2010a) 
developed tg rats with mutant TDP-43 that causes nerve degeneration and aggregates of TDP-43. 
Similar to TDP-43 protein, aggregates of FUS are found in the cytoplasm of MN in patients with no 
pathological changes in TDP-43 or SOD1, suggesting a novel disease pathway (Kiernan et al., 2011). 
The discovery of mutations in TDP-43 and FUS/TLS in fALS and the presence of abnormal TDP-43 in 
sALS opened the development of research on the role of RNA metabolism and processing, which will 
be further explored in section 1.3.1. 
  
1.2. Environmental causes 
It has been proposed that exposure to some chemicals and toxins, viral infection and Prion 
disease, as well as a lifetime of intensive sport or physical exertion, are some of the environmental 
causes that may contribute to ALS onset (Kiernan et al., 2011; Redler and Dokholyan, 2012; Rowland 
and Shneider, 2001). However, most of these reports involve a very small number of cases, which do 
not allow a rigorous evaluation of these factors as potential risks for ALS development (Redler and 
Dokholyan, 2012). Nevertheless, regarding exposure to some toxins, there is increased evidence that 
active smokers have a double risk of developing ALS, compared with people who never smoked 
(Gallo et al., 2009). The most convincing case related with toxins is the association between β-methyl-
amino-L-alanine (BMAA) exposure and the development of an epidemic of ALS-Parkinson’s disease 
on the island of Guam. BMAA is a neurotoxin produced by cyanobacteria and a dietary compound 
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found in the seed of the cycad Cycas cirinalis. These seeds were used to make flour by the Chamorro 
during 1950’s and are also eaten by flying foxes. Consequently, not the consumption of products 
derived from flour, but the consumption of flying foxes provoked an increased  incidence of ALS (Cox 
et al., 2005). In addition, some virus, such enterovirus (Berger et al., 2000), immunodeficiency virus 
and human T-cell lymphotrophic virus type I (Rowland and Shneider, 2001) have been reported in a 
small number of patients who developed ALS symptoms. Lyme disease, an infectious disease caused 
by at least three species of bacteria, may occasionally produce a syndrome with both upper and lower 
MN symptoms, but it did not develop a typical ALS (Berger et al., 2000). 
 
1.3. MN vulnerability  
ALS is a multifactorial disease, with pathophysiological mechanisms that show a complex 
interaction between genetic and molecular pathways, most of them related with the subtype of disease 
caused by mutations in SOD1 (Ferraiuolo et al., 2011). MNs seem to be the main target of injury in 
ALS. The mechanisms that lead to the death of MNs are not completely understood, although 
structural and metabolic specialization could contribute to their vulnerability (Shaw and Eggett, 2000). 
MN are large cells with a cell body of nearly 50-60 μm and an axon of up to 1 m long (Barber and 
Shaw, 2010). Consequently, the cell requires high amounts of energy, necessary for the production 
and transport of cellular components, regulation of messenger ribonucleic acid (mRNA) distribution for 
protein synthesis, maintenance of the membrane potential along the axon and action potential 
generation (Ferraiuolo et al., 2011).  
Those mechanisms include deregulated transcription and RNA processing, oxidative stress, 
mitochondrial dysfunction, excitotoxicity, protein aggregation, deregulated endosomal trafficking, 
endoplasmatic reticulum (ER) stress, cellular death and impaired axonal transport, which will be 
further dissected in this chapter and illustrated in Figure I.2.  
       1.3.1. Deregulated transcription and RNA processing 
Deregulated transcription and RNA processing was first detected in MN degeneration through 
the identification of mutations in survival MN protein or gemin-1 gene (SMN1) by Lefebvre and 
colleagues (1995). This gene  encodes a protein responsible for the assembly of small nuclear 
ribonucleoproteins, important for pre-mRNA splicing (Burghes and Beattie, 2009). Gene expression 
profiling showed a transcriptional repression of mSOD1 in neuroblastoma-spinal cord MN 34 (NSC-34) 
cells stably expressing SOD1G93A (Kirby et al., 2005) and in isolated MN from SOD1 G93A mice with 
late-stage disease (Ferraiuolo et al., 2007).  
TDP-43 and FUS/TLS are proteins present in the nucleus of healthy cells and are involved in 
RNA processing events such as splicing and transcriptional regulation (Lagier-Tourenne et al., 2010). 
The investigations about the mechanisms by which TDP-43 and FUS trigger neurodegeneration are in 
an initial stage; thus, it is still unknown if the neurodegeneration is due to a loss of function of these 
proteins, a gain of toxic properties, or a combination of both, associated with nuclear or cytoplasmatic 
aggregates. The gain of function hypothesis proposes that TDP-43 and FUS/TLS cytoplasmic 
inclusions drive the disease, through an aggregation mechanism (Polymenidou et al., 2012). TDP-43 
and FUS are also involved in the formation of stress granules-cytoplasmic foci containing RNA in 
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complex with RNA-binding proteins that transiently appear to be under cellular stress (Bosco et al., 
2010; Dewey et al., 2011). It may be possible that stress granules transform into pathogenic inclusions 
during neurodegeneration. Additionally, the reception of specific cellular RNAs within cytoplasmic 
TDP-43 and FUS inclusions may deplete the cell of essential RNA components, contributing to 
pathogenesis (Polymenidou et al., 2012). It was reported in ALS patients splicing alterations, some of 
which may be directly related to TDP-43 misregulation (Xiao et al., 2011). Oxidation of mRNA has 
been also identified in ALS patients and tg mice expressing a variety of fALS-linked SOD1 mutations 
(Barber and Shaw, 2010).  
Other genes coding proteins involved in RNA transcription, such angiogenin (ANG) and 
senataxin (SETX) have similarly been object of studies (Ferraiuolo et al., 2011).  
 
1.3.2. Oxidative stress 
Cellular reactive oxidative species (ROS) results mainly from the aerobic metabolism; in fact, 
during oxidative phosphorylation in the mitochondria, there is a “leakage” of the electrons from the 
mitochondrial respiratory chain. Posteriorly, these species react with other compounds to produce 
more potent oxidants (Siegel et al., 2006). These potent oxidants are capable of changing protein 
conformation, alter cellular membrane dynamics by oxidation of unsaturated fatty acids, and cause 
damage in DNA and RNA (Barber and Shaw, 2010). Oxidative stress defines a condition that disrupts 
redox signaling and control, through the damaged compartmentalized cellular redox circuits (Jones, 
2006). 
ALS-vulnerable MN are particularly susceptible to oxidative stress, since they have low 
endogenous calcium buffering capacities, which occur due to the low expression of cytosolic calcium-
binding proteins (Barber and Shaw, 2010). Consequently, it allows a fast recovery time of activity-
related calcium transients at a relatively low energy cost, which is useful in the practice of motor 
activities like running or breathing (Lips and Keller, 1999). On the other hand, low buffering capacities 
leads to formation of large volume calcium micro-domains around open channels, mainly near 
mitochondria (von Lewinski and Keller, 2005). Consequently, mitochondria pick up more free calcium, 
triggering an increase in ROS production and contributing to oxidative stress (Barber and Shaw, 
2010). Moreover, MN  have a high threshold for mounting a protective heat shock response, 
increasing sensitivity to ER stress and mitochondrial features (Ferraiuolo et al., 2011). 
It is still debated if oxidative stress is a primary cause of degeneration or results from another 
toxic insult in the pathogenesis of ALS. In fact, identification of ALS associated SOD1 mutations 
revealed oxidative stress as a primary driver in ALS pathogenesis (Barber and Shaw, 2010). 
Moreover, oxidative stress aggravates other pathophysiological processes involved in 
neurodegeneration, such as excitotoxicity (Rao and Weiss, 2004), mitochondrial impairment (Duffy et 
al., 2011), protein aggregation (Wood et al., 2003) and ER stress (Kanekura et al., 2009), besides 
being an underlying cause for alterations in signaling from astrocytes (Blackburn et al., 2009) and 
microglia (Sargsyan et al., 2005). Indeed, studies of cerebrospinal fluid (CSF) and human postmortem 
CNS tissue from ALS patients showed biochemical changes that represent the effect of free radical 
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damage or abnormal free radical metabolism (Ferrante et al., 1997; Shaw et al., 1995; Smith et al., 
1998; Tohgi et al., 1999). 
SOD1 plays an important role as an antioxidant. So, the accumulation of this enzyme in wild 
type (wt) or mutated state influences this mechanism. Transgenic mouse models of ALS expressing 
human mSOD1 showed increased oxidative damage at the level of proteins, lipids and DNA (Casoni 
et al., 2005; Liu et al.,1999; Poon et al., 2005). Moreover, mSOD1 itself was the most severely 
oxidized protein in the SOD1 G93A mouse (Andrus et al., 1998). As previously mentioned, it is known 
that mSOD1 is toxic through an unknown gain of function. For example, beyond catalyzing SOD 
radicals, SOD1 also acts as a peroxidase, producing hydroxyl radicals, using H2O2 as a substrate (Yim 
et al., 1990). Alternatively, mutations in SOD1 may difficult the enzyme to bind zinc (Estevez et al., 
1999), which will impede the elimination of ROS by both mutant and wt SOD1. An hypothesis is that 
this impossibility of SOD1 to bind zinc will favor the reducing agents to react with oxidized calcium  at 
the active site, and consequently more production of superoxide, which reacts with nitric oxide (NO) to 
produce peroxynitrite, will ultimately cause tyrosine nitration (Barber and Shaw, 2010). Indeed, studies 
in SOD1 G93A mice with zinc deficiency showed acceleration in the disease progress (Ermilova et al., 
2005).  
Some studies of MN expressing mSOD1 showed down-regulation of genes involved in the 
antioxidant response, such as the transcription factor nuclear erythroid 2 – related factor 2 (Nrf2). 
Activation or Nrf2 determines its translocation from the cytoplasm to the nucleus, where it interacts 
with the antioxidant-response element (ARE) sequence to increase the expression of proteins with 
antioxidant function (Nguyen et al., 2009). Down-regulation of Nrf2 expression will reduce the capacity 
to remove ROS, which has been reported in mSOD1 models of ALS (Kirby et al., 2005) and in the 
CNS of patients with ALS (Sarlette et al., 2008).  
Finally, it was reported the role of microglial mSOD1. It can increase the production of 
superoxide by nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase), through the 
blockage of Rac1 into its active state in the Nox complex (Harraz et al., 2008). The increasing of Nox2 
expression was detected in mSOD1 mice and in the CNS of patients with ALS. Interestingly,  knockout 
of Nox1 or Nox2  revealed to  increase the survival rate of SOD1 G93A (Ferraiuolo et al., 2011).  
1.3.3. Mitochondrial dysfunction 
Mitochondria are responsible for the generation of energy, through the production of 
adenosine triphosphate (ATP), as well as to maintain calcium homeostasis and regulation of the 
initiation of apoptotic cell death (Pizzuti and Petrucci, 2011). Besides that, mitochondria generate free 
radicals, as mentioned in the previous section, which are the main cause for oxidative damage. 
Moreover, the requirement of high amounts of energy by MN promotes an intense mitochondrial 
activity and a consequent production of higher quantity of ROS, contributing to a consequent oxidative 
stress event (Genova et al., 2004).  
In fact, mSOD1 provokes dysfunction and structural damage of mitochondria in human 
patients and mouse models of ALS (Higgins et al., 2003). In SOD1 G93A mice, SOD1 aggregates 
were observed in vacuoles and mitochondrial intermembrane space, at an early stage of the disease 
(Higgins et al., 2002). Mutant SOD1 also accumulates in mitochondrial outer membrane, impeding 
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protein import (Vande Velde et al., 2008), and binds directly to the voltage-dependent anion channel 
(VDAC), depolarizing the membrane and contributing to the abnormal function of electron transport 
chain, thus increasing ROS production (Mattiazzi et al., 2002).  
The disturbance of mitochondrial function by mSOD1 causes cell death through the activation 
of the apoptotic cascade. Some of the mechanisms that trigger apoptosis are the release of 
cytochrome c (Kirkinezos et al., 2005) and the binding of mSOD1 to the pro-survival factor B-cell 
lymphoma 2 (Bcl-2) (Pedrini et al., 2010).  
Excitotoxic events trigger a high calcium influx in response to glutamate. Consequently, 
elevation of cytosolic calcium levels in neurons induce enhanced production of free radicals from 
mitochondria. Transgenic mouse with mSOD1 G93A also presents a significant decrease in 
mitochondrial calcium loading capacity in brain and SC (Damiano et al., 2006). In a neuronal model 
with mSOD1 G93A, it was observed a morphologic swollen mitochondria, impaired activity in electron 
transport chain, compromised cellular bioenergetic status and alterations in mitochondrial proteome 
(Fukada et al., 2004; Menzies et al., 2002). In addition, in these cellular models, it was verified a 
deceleration of fast axonal transport of mitochondria and other membrane bound organelles, caused 
by energy supply in MN (De Vos et al., 2007; Zhang et al., 2007). 
 
1.3.4. Excitotoxicity 
Glutamate is the main excitatory neurotransmitter in the CNS and exerts its effects through an 
array of ionotropic and metabotropic postsynaptic receptors. G protein-coupled receptor is a 
metabotropic receptor, which leads to the release of intracellular calcium stores when activated. 
Glutamate-gated ion channels are ionotropic receptors, which subdivide in N-methyl-D-aspartic acid 
(NMDA), a calcium permeable channel, and in non-NMDA, a channel whose calcium permeability 
varies with the subunit composition. α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) is 
a non-NMDA channel that has a subunit called GluR2, whose activity depends on post-transcriptional 
editing of GluR2 mRNA. When this subunit is present, the channel is impermeable to calcium; when 
AMPA lacks GluR2 subunit, it becomes calcium permeable (Siegel et al., 2006).  
To remove glutamate from the synaptic cleft, there are the excitatory amino acid transporters 
(EAATs), predominating the EAAT2, also called glutamate transporter-1 (GLT1), mainly in astrocytes 
located near post-synaptic neurons (Rowland and Shneider, 2001). 
Excitotoxicity results from excessive activation of glutamate receptors and may be caused by 
an increased sensitivity of the post-synaptic neuron to glutamate or by increased synaptic levels of 
glutamate (Van Damme et al., 2005). It could disrupt intracellular calcium homeostasis, contributing to 
the damage of intracellular organelles, perturbation of ATP production and activation of proteolytic and 
ROS-generating enzyme systems (Arundine and Tymianski, 2003). MN are particularly sensible to 
glutamatergic toxicity via AMPA receptor activation, since they have a high expression of this receptor 
lacking the GluR2 subunit (Williams et al., 1997). Consequently, during an excitotoxic event, elevated 
concentrations of calcium enter in the cell and are captured by mitochondria, contributing to ROS 
production (Carriedo et al., 2000). Studies demonstrated that the levels of glutamate in CSF of some 
patients with ALS are elevated (Rothstein et al., 1992). It has also been observed hyperexcitability of 
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the motor system at early stages of the disease using transcranial magnetic stimulation techniques in 
conjunction with peripheral nerve excitability studies in humans (Vucic and Kiernan, 2006).   
Another via excitotoxicity is the selective loss of EAAT2. This loss can be associated to an 
aberrant splicing of EAAT2 mRNA in affected regions of the CNS (Lin et al., 1998). Consequently, 
glutamate remains in the environment and continues to activate their receptors (Musaro, 2010). 
Indeed, patients with sALS and fALS, as well as mSOD1 rat, have all presented decreased levels of 
EAAT2 (Fray et al., 1998; Howland et al., 2002). 
 
1.3.5. Protein aggregation  
In normal cellular behavior, protein control is maintained by the activation of protein 
chaperones and ubiquitin-proteasome system (UPS), preventing the toxic effects of mutant proteins.  
However, under cases of physiological or environmental stress, this system becomes overloaded and 
impaired (Kabashi and Durham, 2006). One of those cases is the occurrence of extra- or intracellular 
fibrillar aggregates that contain β-sheet conformation, which constitutes an important feature of ALS 
(Musaro, 2010). Many cytoplasmic aggregates from different proteins were found in fALS cases, such 
as SOD1, TDP-43 and FUS (Ferraiuolo et al., 2011).  
In SOD1 tg mouse, insoluble inclusion bodies of SOD1 appear in brain stem and in SC, 
coincident with symptom onset, and accumulate progressively in the terminal stages, causing 
symptoms only when UPS cannot destroy SOD1 aggregates (Redler and Dokholyan, 2012). 
Aggregates of SOD1 were also observed in cell culture models and in SOD1-linked fALS patients 
(Ferraiuolo et al., 2011). Many hypothesis have been proposed to explain how mSOD1 aggregates 
trigger cell toxicity. One of them is the sequestration by these aggregates of other proteins required for 
normal MN function (Shaw, 2005). Another option are the continued misfolding of SOD1 aggregates, 
that maintain chaperone constantly occupied, preventing the access of other proteins necessary for 
folding or function (Bruening et al., 1999). Additionally, mSOD1 aggregates could reduce proteasome 
activity needed for normal protein turnover (Allen et al., 2003) and, finally, mSOD1 could inhibit the 
function of specific organelles by their aggregation on them or even in their inside (Shaw, 2005).  
TDP-43 forms aggregates that have an ultrastructural similarity to TDP-43 deposits in 
degenerating neurons of ALS patients. The C-terminal domain of TDP-43 is crucial for spontaneous 
aggregation, leading to a distribution of inclusions along the cytoplasm (Johnson et al., 2009). The 
presence of these aggregates may be a pathogenic marker in sALS and fALS (Sreedharan et al., 
2008).  
Finally, cytoplasmic inclusions containing mutant FUS have been observed in some patients 
with FUS-related fALS (Ferraiuolo et al., 2011), providing several important clues about the new 
disease pathway, once no SOD1 or TDP-43 aggregates are found (Kiernan et al., 2011). 
 
1.3.6. Deregulated endosomal trafficking 
Endocytosis is a process for moving a wide variety of molecules from the cell periphery into 
the cytoplasm of the cell. Specific cargo molecules are transported and delivered to the correct 
destination within the cells. This transport are mediated by vesicles and/or vacuoles, which then 
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mature or fuse with early endosomes, before the cargos are delivered to their end destinations (Otomo 
et al., 2012). Endocytosis are controlled and composed by a variety of molecules, whose mutations 
have been implicated in several genetic subtypes of ALS. Alsin is a guanine nucleotide exchange 
factor for the small GTPase protein Rab5 and is involved in endosomal fusion and trafficking, as well 
as neurite outgrowth (Ferraiuolo et al., 2011). One form of juvenile onset autosomal recessive ALS 
(ALS2) has been linked to the loss of function of the alsin gene (Yang et al., 2001). Most mutations in 
this gene lead to premature stop codons, resulting in carboxyl-terminal truncated proteins that are 
unstable, compared with the wt alsin (Yamanaka et al., 2003). Loss of function of alsin causes the 
degeneration of MN, but the pathogenic mechanisms of ALS2 remain unknown (Lai et al., 2006). 
Vesicle associated membrane protein-associated protein B (VAPB) is a protein resident in 
endoplasmic reticulum (ER) which is possibly involved in unfolded protein response (UPR). Indeed, 
studies refer that mutations in this gene constitute a risk factor for MN disease mediated by loss of its 
function (Kabashi et al., 2013). More rare mutations in genes coding optineurin (Maruyama et al., 
2010), charged multivesicular protein 2B (Parkinson et al., 2006) and valosin-containing protein 
(Johnson et al., 2010) have also been described in ALS. 
 
1.3.7. Endoplasmatic reticulum stress 
 
The ER is responsible for translation, folding and transport of membrane proteins and 
secreted proteins. It also stores high calcium levels and interacts closely with mitochondria by 
exchanging calcium in a cyclic manner, which is thought to synchronize energy demand and rates of 
protein folding, and also to initiate apoptosis. It interacts closely with the nucleus and the Golgi 
apparatus to direct proteins to axonal transport and exocytosis, and protein degradation pathways. ER 
can recognize aberrant proteins and refold them through the activation of ER chaperones such as 
binding immunoglobulin protein (BiP) or drive out them through the ER-associated protein degradation 
(ERAD) pathway, activating UPR (Siegel et al., 2006). When there are problems in calcium exchanges 
or the accumulation of misfolded proteins, ER stress can be triggered (Schroder, 2008). Studies 
showed that markers of ER stress are up-regulated in the CSF and SC of patients with sALS, as early 
features in ALS (Ferraiuolo et al., 2011). For example, Atkin and colleagues (2008) identified the 
activation of protein disulphide isomerase (PDI), an ER chaperone and a marker of the UPR derived 
from the presence of mSOD1 inclusions, both in mSOD1 mice and in autopsies from patients with 
sALS. PDI and other UPR-induced proteins are up-regulated at the beginning of the disease in 
mSOD1 rodents, reinforcing the concept that ER stress is involved in the onset of MN injury (Atkin et 
al., 2008). Nishitoh and colleagues (2008) found that mSOD1 interacts with ER-associated 
degradation ERAD protein Derlin-1, a transmembranar protein responsible for the translocation of 
misfolded proteins from the ER lumen, in mouse neuronal tissue, leading to ER stress-mediated cell 
death through apoptosis and stimulating kinase-1. Vijayalakshm and colleagues (2011) exposed MN-
like cells and MN to CSF from patients with ALS and observed an increase in ER stress, which 
included expression of UPR markers, ER fragmentation and caspase-12 activation. Mutations in 
VAPB gene are also involved in ER stress, since it forms aggregates through conformational changes 
(Chen et al., 2010). 
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   1.3.8 – Cellular Death 
Apoptosis is a form of programmed cell death, which includes several morphological and 
biochemical changes that characterize and permit the identification this type of cell death. Interveners 
in this event include: a) caspase family of proteolytic enzymes responsible for the destruction of 
structural and regulatory proteins; b) the Bcl-2 family of oncoproteins, which are associated with the 
mitochondrial membrane and modify its permeability; and c) apoptosis inhibitor family of proteins that 
prevents proteolytic activation of specific caspases and, therefore, apoptosis (Siegel et al., 2006). 
In ALS, it is accepted that MN die by a programmed cell death pathway and biochemical 
markers of apoptosis were found in the terminal stages of human and in tg mice. Mutated SOD1 is 
involved in the activation of apoptosis in cultured neuronal cells either transfected or microinjected with 
mSOD1 complementary DNA (cDNA), evidenced to suffer apoptosis (Durham et al., 1997; Pasinelli et 
al., 1998). Mitochondria also participate in apoptosis, through the release of pro-apoptotic factors, 
such as cytochrome c. In ALS tg mice, it was observed an impairment in the association of 
cytochrome c with the inner membrane of the mitochondrion, leading to its release to cytoplasm with 
subsequent activation of the apoptotic cascade (Bacman et al., 2006). Activation of caspases is 
associated with MN degeneration. In the SOD1 G85R mice, caspase-1 is activated months before 
caspase-3 activation, MN death and clinical onset (Pasinelli et al., 2000). In SOD1 G93A mice, and 
accordingly to caspase activation sequence, the cytochrome c translocation into the cytosol activate 
caspase-1, followed by the activation of caspase-9 which, at least, trigger caspase-3 and -7 activation. 
In this same model, the activation of caspase-7 was shown to match with ALS onset (Guegan et al., 
2001).  
Some other pathways related with the anti-apoptotic Bcl-2 protein were reported to promote 
apoptosis. One of them is the entrapment of Bcl-2 into both wt and mSOD1 aggregates, switching the 
protein to a non-functional stage (Pasinelli et al., 2004). Another hypothesis is related with their 
conformational modification that results from their binding to mSOD1, leading to the production of a 
toxic protein (Pedrini et al., 2010). Before these observations were made, Kostic and colleagues 
(1997) have shown that, in contrast, overexpression of Bcl-2 preserved motor function and extended 
the life span in SOD1 G93A mice. 
Contrary to apoptosis, necrosis is not a developmentally programmed type of cell death. 
Instead, cells swell, nuclear membrane disrupts, mitochondria and ER lose their structure and become 
dysfunctional. It is independent of pre-mitochondrial apoptotic proteins and results from a traumatic 
physical injury or stroke. It affects a large amount of cells, whereas apoptosis typically occurs in 
individual cells within a population of surviving neighbors. Typically, the cellular contents are released 
into the extracellular space and damage neighboring cells to evoke an inflammatory response, while in 
apoptotic events, each cell forms a vesicle (Siegel et al., 2006). Necrotic cell death may also occur in 
many neurodegenerative diseases, including ALS. However, it is not well studied the mechanisms that 
trigger this particularly type of event. Studies indicate that necrosis of adult neurons is mediated by 
increases of intracellular calcium and the major players are cytosolic calpains and spilled lysosomal 
cathepsins. Cellular energy depletion is a potent trigger of necrosis mediated by excitotoxicity (Artal-
Sanz and Tavernarakis, 2005). Acidification, produced by oxygen depletion, also plays an important 
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role in necrotic neuronal death (Ding et al., 2000). Acidosis activates calcium-permeable acid sensing 
ion channels, resulting in glutamate receptor-independent neuronal injury due to calcium toxicity 
(Xiong et al., 2004). Moreover, toxic mutations in several genes can trigger necrotic cell death. 
Necrosis-like neuronal death was shown to be also determined by gain-of-function mutations in genes 
that encode the ion channel proteins termed degenerins (Hall et al., 1997).  
Autophagy, that constitutes a protein clearing system, is composed by three categories: 
macroautophagy, microautophagy and chaperone-mediated autophagy. Macroautophagy is 
characterized by the involvement of organelles with an intracellular membrane to isolate them from 
cytoplasm, forming a structure called autophagosome. The compartment is then acidified and fuses 
with lysosome for degradation. Microautophagy is responsible for the turnover of organelles and 
recycling of biological building blocks. In this case, the organelle fuses directly with lysosome and is 
degraded.  Chaperone-mediated autophagy is a mechanism used to import cytoplasmic proteins into 
lysosomes for degradation. The proteins targeted for degradation are tagged with a particular peptide 
motif, which is recognized by a chaperone. Then, the chaperone–protein complex binds to a specific 
lysosomal membrane receptor for import into the lysosome (Siegel et al., 2006). The macroautophagic 
pathway has been implicated in several neurodegenerative diseases, including ALS. Kabuta and 
colleagues (2006) have demonstrated in cellular models that wt and mSOD1 are degraded by 
macroautophagy. As it reduces the toxicity of mSOD1 proteins, it is proposed that macroautophagy is 
important for the reduction of mSOD1-mediated neurotoxicity in fALS. However, macroautophagy may 
disturb the cell homeostasis and lead to cell death when autophagy is over-activated, contributing for 
the pathogenesis of ALS (Pattingre et al., 2005). Studies in SOD1 G93A mice reported an alteration of 
autophagy in the beginning of the pre-symptomatic stage of ALS. Compared with the age-matched 
controls, the number of Microtubule-associated protein 1A/1B-light chain 3 (LC3)-labeled autophagic 
vacuoles were significant increased in the MN of the SC from SOD1 G93A mice (Li et al., 2008). 
Increased autophagy was suggested to be partially regulated by a mammalian target of rapamycin 
(mTOR) signaling pathway (Morimoto et al., 2007). Besides mSOD1, the existence of mutations in 
other genes may also determine a defective autophagy (Caccamo et al., 2009; Parkinson et al., 2006). 
 
1.3.9 - Impaired axonal transport 
MN are high polarized cells with long axons and a  cytoskeleton  composed by neurofilament 
(NF) proteins that which ensures the maintenance of cell shape, axonal caliber and delivery of 
essential components, such as RNA, proteins and organelles to the axonal compartment (Siegel et al., 
2006). NF proteins include light (NF-L), medium (NF-M), and heavy (NF-H) subunits, in equal 
proportion, which are progressively phosphorylated during axoplasmic transport. Axonal transport 
between the cell body and neuromuscular junction (NMJ) is made by microtubule-dependent kinesin 
and cytoplasmic dynein/dynactin molecular motor, which mediates anterograde transport (toward 
NMJ) and retrograde transport (toward cell body), respectively (Duncan and Goldstein, 2006).  
Over- or under-expression, mutation or deficient transport of individual subunits determine 
misassembly of neurofilaments leading to  their accumulation and thus determining impairment of 
axonal transport and resultant  MN death (Redler and Dokholyan, 2012). Abnormal accumulation of 
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neurofilaments is a pathological feature ALS and occurs as an early event (Shaw, 2005), which has 
been observed in both patients with sALS and fALS (Hirano et al., 1984), as well as in SOD1 G93A 
mice (Rouleau et al., 1996).  
There is not a clear hypothesis about how the aberrant expression of neurofilaments originates the 
degeneration of MN. The axonal transport of molecules can be disrupted by the disorganization of 
neurofilaments, process known as “axonal strangulation”, that may derive from mSOD1 toxic effects 
(Collard et al., 1995). Thus, reduction  of the number of axonal neurofilaments, evidence to protect 
from the  mSOD1 toxic effects (Rowland and Shneider, 2001).  On the other hand, the accumulation of 
neurofilaments could exert a protective effect against mSOD1 through buffering calcium, providing 
more phosphorylation sites for deregulated intracellular kinases, or reducing the burden of axonal 
transport or diminishing zinc binding (Rowland and Shneider, 2001; Shaw, 2005).  The exclusion of 
the light subunit of neurofilaments (Williamson et al., 1998) or overexpression of the NF-H subunit 
(Couillard-Despres et al., 1998) was observed to ameliorate ALS in mSOD1 mice. 
A reduced expression of NF-L was also observed in different models, such as sALS and fALS 
cases, tg mice and in a cell culture model of ALS, where an alteration of stoichiometry of 
neurofilament subunits was observed (Barber and Shaw, 2010). Mutations in the gene coding NF-H 
subunit were also found in sALS and fALS patients (Al-Chalabi et al., 1999).  
The anterograde and retrograde transport are impaired by the presence of mSOD1 and 
mitochondria trafficking suffer retardation, leading to a defective transport of other cargoes, once the 
cell lacks energy (De Vos et al., 2007). This may explain the early onset distal axonopathy observed in 
ALS mouse models and the accumulation of mitochondria in proximal axons in sALS patients (Redler 
and Dokholyan, 2012). Other factors may account to impaired axonal transport. Indeed, tumor 
necrosis factor (TNF) may cause kinesin disruption, via a mechanism involving p38 mitogen-activated 
protein kinase (p38 MAPK), as observed in L929 cell line (De Vos et al., 2000) and glutamate by 
activating protein kinases, which phosphorylate neurofilament proteins (Ackerley et al., 2000). 
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Figure I.2 – Amyotrophic Lateral Sclerosis (ALS) is a multifactorial disease, with pathophysiological 
mechanisms that show a complex interaction between genetic and molecular pathways, most of them 
related with the subtype of the disease caused by diverse mutations in superoxide dismutase 1 (SOD1). 
Mutations in several ALS-related genes, oxidative stress and mitochondrial alterations can be responsible for the 
formation of protein aggregates, which are harmful for neurons. These aggregates lead to proteasome impairment 
and endoplasmic reticulum (ER) stress, and ultimately activate autophagy and apoptotic pathways. Autophagy 
begins with the formation of a phagophore, which expands to cover portions of cytoplasm containing proteins and 
organelles into the autophagosome. It is assisted by p62, linking ubiquitinated protein aggregates and LC3. After 
that, autophagosomes are trafficked along microtubules in a dynein-dependent way to lysosomes. Then, they 
enter in a maturation phase, through the fusion with endosomal vesicles or multivesicular bodies, followed by 
fusion with lysosomes, forming the autolysomes. In ALS there is an increased expression of the autophagic 
marker LC3-II, showing the activation of this via in the degradation of SOD1. However when autophagy is 
overactivated, there is a disturbance of the cell homeostasis, leading to cell death. Mitochondrial dysfunction is 
characterized by a decrease of the respiratory chain activity, adenosine triphosphate (ATP) levels, together with 
the release of the cytochrome c with consequent activation of the apoptotic cascade. This dysfunction promotes 
an increase in the production of reactive oxygen species (ROS), leading to oxidative stress. Excitotoxicity 
mediated by glutamate leads to an overstimulation of N-Methyl-D-aspartate (NMDA) receptors and accumulation 
of calcium (Ca2+) ions in cellular compartments, which further leads to ER stress and activation of apoptotic 
pathways. Transcriptional deregulation and abnormal RNA processing, together with overproduction of ROS, also 
contribute to aberrant protein folding. Accumulation of neurofilament intracellular aggregates disrupts axonal 
transport processes, thus blocking the energy supply to the distal axon. Adapted from Ferraiuolo et al. (2011).  
 
1.4. The role of glial cells and cross-talk with neurons in ALS  
Initially, ALS was considered a cell autonomous disease, where MNs were the only cells affected. 
In fact, many studies in genetically engineered mouse models were made to develop disease from the 
expression of mSOD1 only in MN, most of them without success (Lino et al., 2002; Pramatarova et al., 
2001). Only one that used mSOD1 expression driven by neuron-specific Thy1.2 promoter appeared to 
cause MN death (Jaarsma et al., 2008). However, more recently, many findings showed the 
intervention of non-neuronal cells, such as microglia and astrocytes, in the pathogenesis of the 
disease (Ferraiuolo et al., 2011). Several studies showed a reduction in MN survival when cultured 
with mSOD1-expressing glial cells. Di Giorgio and colleagues (2007) have used pathogenic MN 
derived from embryonic stem cells carrying G93A mutation and wt MNs to be co-cultured with 
SOD1G93A glial cells. Mutant glia revealed to induce signs of neurodegeneration in both wt and 
mSOD1 neurons. By the other side, removal of mSOD1 expression in either astrocytes or microglia 
using glial fibrillary acidic protein-Cre (GFAP-Cre) or CD11b-Cre transgenes, respectively, slowed the 
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disease progression and  boosted the survival of ALS mice (Boillee et al., 2006; Yamanaka et al., 
2008b). However, the individual contribution of each cell is still a matter of debate. Actually, when the 
expression of mSOD1 was restricted to microglia or astrocytes the disease was not induced (Beers et 
al., 2006). Nevertheless, other studies point to astrocytes expressing mSOD1 as causing MN 
degeneration when using an in vitro model of ALS (Nagai et al., 2007). 
 
1.4.1. Astrocytes 
Astrocytes, the most abundant nerve cell types in the adult CNS, are responsible for the 
maintenance of the extracellular homeostasis through the modulation of ions and neurotransmitters, 
nutrients supply and release of growth factors. They also have a structural function, whose 
membranes cover synaptic contacts and establish contacts with neuronal membranes as well as with 
blood (Siegel et al., 2006). In case of injury, astrocytes become activated in a process called 
astrogliosis, characterized by altered cell morphology, hypertrophic nuclei, increase prominence of 
processes, up-regulation of intermediate filament GFAP (Pekny and Nilsson, 2005) and release of pro-
inflammatory factors (Phani et al., 2012), as shown in Figure I.3. These characteristics were observed 
in both SC and brain motor regions in mSOD1 mice, as well as in human ALS cases (Hall et al., 1998; 
Kassa et al., 2009; Nagata et al., 1998).  
Alterations in astrocytic function, may involve the loss of the EAAT2 transporter and the 
consequent increase of extracellular glutamate, as observed in SCs of both sALS and fALS (Fray et 
al., 1998; Rothstein et al., 1995), as shown in Figure I.3. Similar features were noticed in the SCs of 
mSOD1 tg mice (Bruijn et al., 1997) and rats (Howland et al., 2002), resulting in neuronal 
excitotoxicity, as previously discussed in section 1.3.4. A recent study performed by Diaz-Amarilla and 
colleagues (2011), which created primary astrocyte cultures from symptomatic SOD1 rat SCs, 
identified a high proliferation of a subset of astrocytes, expression of GFAP and other astrocyte 
markers, a phenotype that they designated as “aberrant astrocytes”, and also include the  absence of 
EAAT2, further confirming previous findings.  
Activated astrocytes, if releasing insufficient quantity of neurotrophic factors, may impair MN once 
they are essential in promoting neuronal survival (Ekestern, 2004). Among such factors are the glial-
derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic 
factor (CNTFR) and vascular endothelial growth factor (VEGF) (Dewil et al., 2007b; Ekestern, 2004), 
as we can see in Figure I.3. Additionally, mSOD1 astrocytes may release toxic products, such as pro-
inflammatory cytokine oxidative stressors (Phani et al., 2012) and neurotrophic growth factor (NGF), 
which induce the death of MN expressing the receptor p75 through a mechanism involving the 
synthesis of NO and peroxide (Pehar et al., 2004). Fas ligand and TNF-α produced by reactive 
astrocytes can also activate death receptors in injured MN (Raoul et al., 2002). Moreover, astrocytes 
respond to toxic factors in CSF of ALS patients by undergoing morphological transformation from flat 
to process bearing and by expressing elevated levels of GFAP and S100A6 and S100B proteins 
(Shobha K, et al., 2010). 
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1.4.2. Oligodendrocytes and Schwann cells 
Oligodendrocytes are the most important glial cells responsible for myelination of upper motor 
axons and, more recently, to also be involved in axonal energy supply and metabolism (Lee et al., 
2012). Recent studies propose a contribution of these cells in the neuropathology of ALS. Seilhean 
and colleagues (2009) found p62 and TDP-43 positive intracytoplasmic inclusions in oligodendrocytes, 
while MacKenzie and colleagues (2011) found FUS-positive inclusions in these glial cells. A study of 
human ALS post mortem tissue showed loss in the number of small fibers, most likely due to intrinsic 
SC lesions, and diffuse myelin pallor in the anterolateral columns associated with microglial infiltration 
(Hayashi et al., 2001). Studies in SC myelin from SOD1 G93A
 
rats in fully symptomatic stages of the 
disease found a disorganization of myelin, and reduced levels  of lipids, phospholipids and cholesterol 
(Niebroj-Dobosz et al., 2007), as shown in Figure I.3. Recently, Philips and colleagues (2013) showed 
degenerative changes in oligodendrocytes in human patients with ALS and in mSOD1 mouse model. 
On the contrary, some studies suggested that oligodendrocytes might not be an important element in 
the disease pathology. Indeed, Yamanaka and colleagues (2008a) by examining chimeric mice, 
whose all MN and oligodendrocytes express high levels of mSOD1, observed that the disease onset 
was delayed, supporting that cell types excluding MN and oligodendrocytes must be major 
contributors to ALS disease onset and progression. 
Schwann cells are responsible for the myelination and regeneration of lower motor axons, 
providing electrical isolation, essential for fast signal conduction (Siegel, 2006). In case of axonal 
damage, they also participate, together with peripheral macrophages, in clearing debris and 
participating in the recovery of axons (Ilieva et al., 2009). Many studies showed a limited and 
unexpected involvement of these cells in ALS disease progression.  Turner and colleagues (2010) 
showed that expression of SOD1 G93A in Schwann cells did not trigger MN degeneration, once no 
alterations were observed between control and mutated mice; additionally the increase of mSOD1 
expression in Schwann cells was shown to not exacerbate the disease phenotype (Figure I.3). 
Moreover, Lobsiger and colleagues (2009) reported that SOD1 G37R expressed in Schwann cells 
slowed the ALS progression, while it was accelerated when the mutant was inactivated by Cre-
mediated gene excision. In contrast to the effects produced by other mutated glial cells and their 
influence on disease progression, these features point to the protective effect that mutated Schwann 
cells may have. 
 
1.4.3. Microglia  
Microglia are cells derived from the hematopoietic cell lineage and are considered the CNS 
tissue-resident macrophage population in the brain parenchyma. They are considered the primary 
immune cells of the CNS, being responsible for monitoring the environment and respond to infection 
and injury (Siegel et al., 2006). Under physiological conditions, the cells exhibit a deactivated 
phenotype, associated with the production of anti-inflammatory and neurotrophic factors (Streit, 2002). 
In response to a pathogen invasion or tissue damage, microglia switch to an activated phenotype, 
promoting the inflammatory response through morphology changes, migration to the damaged cells 
and release of proinflammatory molecules (Lasiene and Yamanaka, 2011), as shown in Figure I.3. 
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Microgliosis has been known to be a component of ALS pathology in the past 20 years (Engelhardt 
and Appel, 1990). Evidence of microglial activation in the brain of living ALS patients, using positron 
emission tomography (PET), was reported by Turner and colleagues (2004). Weydt and colleagues 
(2004) showed for the first time the role of mSOD1expression in primary cultured microglia from 
mSOD1 tg mice, in which microglia produced higher levels of TNF-α and released lower levels of 
interleukin-6 (IL-6), comparatively with wt microglia, when stimulated with lipopolysaccharide (LPS). 
Later, in microglia/MN co-cultures, SOD1 G93A microglia induced more MN death and decreased 
neurite number and length as compared with wt microglia, where NO produced by microglia may have 
had a key role (Xiao et al., 2007).  
To evaluate the role of microglia in ALS progression, Boillee and colleagues (2006), by excising 
mSOD1 from microglia in SOD1 G37R mice using the Cre-Lox system, observed that the intervention 
resulted in a slower disease progression. Similar results were obtained in the SOD1 G85R mice. 
(Wang et al., 2009). Other studies, using replacement of microglia via bone marrow transplantation in 
SOD1 G93A mice, demonstrated that although  not affecting the disease onset, microglia were able to 
slow the disease progression (Beers et al., 2006). It was also observed by Gowing and colleagues 
(2008) that the disease progression does not require the proliferation of mSOD1 microglia in response 
to an initial injury, once reduction of proliferating microglia by half did not affect the progression rate.  
Thus, the role of microglia is complex, once they are capable of stimulating neuroprotective as 
well as neurotoxic effects. This dissertation is focused to better dissect the role of microglia in ALS. 
These properties and influence of microglia in ALS will be further detailed in the section two of this 
introduction. 
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Figure I.3 - Glial cells establish a cross-talk with motoneurons (MNs) in Amyotrophic Lateral Sclerosis. 
Many studies showed the intervention of mutated superoxide dismutase 1 (mSOD1)-expressing non-neuronal 
cells in the pathogenesis of the disease. In case of injury, astrocytes become activated in a process called 
astrogliosis, characterized by the up-regulation of intermediate filament glial fibrillary acidic protein (GFAP) and 
increased levels of toxic products in the extracellular media, such as pro-inflammatory cytokines, oxidative 
stressors and neurotrophic growth factor (NGF). On the other hand, there is a loss of the excitatory aminoacid 
transporter-2 (EAAT2), which can cause neuronal excitotoxicity and an insufficient release of neurotrophic factors, 
essential to promote neuronal survival. These factors include glial-derived neurotrophic factor (GDNF), brain-
derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTFR), and vascular endothelial growth factor 
(VEGF). In addition, it was observed disorganization of myelin, a decrease of lipids, phospholipids and cholesterol 
in activated oligodendrocytes. On the other hand, in Schwann cells, it was verified that an increase of mutant 
SOD1 expression and activation of oxidative cascade slowed ALS progression. Finally, when mutant SOD1 
accumulates within microglia, they increase their proliferation and phagocytic abilities and the production of pro-
inflammatory molecules, such as the tumor necrosis factor alpha (TNF-α) or interleukin-1 beta (IL-1β), reactive 
oxygen species (ROS) and nitric oxide (NO). 
 
1.5. Controversy in ALS—where does the disease begin? 
It is not yet established where ALS begins, once it impacts either in UMN as in LMN, or even in 
both. One hypothesis is that ALS begins in cortico-MN, which connect monosynaptically with anterior 
horn cells and, via glutamate excitotoxicity, mediates anterograde degeneration of anterior horn cells – 
dying-forward hypothesis (Kiernan et al., 2011). Miller and colleagues (2006), for instance, suggest 
that muscle is not a primary target for non-cell autonomous toxicity in fALS. They found that reducing 
mSOD1 within the muscle, through the use of lentivirus that encodes small interference RNA (siRNA), 
directed against mSOD1 or the selective excision of mSOD1 gene from muscle, did not impact in the 
disease. Moreover, the production of chronic muscle hypertrophy through stimulation of myogenesis 
did not slow the disease (Miller et al., 2006; Shaw and Ince, 1997). Towne and colleagues (2008) 
showed that a reduction by more than 50% of SOD1 G93A levels in mouse muscles did not alter the 
course of disease, proving again that SOD1-mediated damage within skeletal muscles does not 
contribute to death of MN in ALS. Additionally, some clinical observations reinforce this hypothesis: (i) 
MN lacking a monosynaptic connection with cortico-MN, such as the oculomotor, abducens, and 
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Onuf’s nuclei, are resistant to neurodegeneration; (ii)  ALS do not naturally develop in the animal 
model due to a shortage of cortico-motor neuronal-anterior horn cell connections; (iii)  the rare 
appearance of pure LMN forms of ALS, whereas subclinical UMN involvement is invariably detected 
with transcranial magnetic stimulation studies (Kiernan et al., 2011).  
Another concept supports that ALS begins inside the muscle cells or at the NMJ – dying-back 
hypothesis. In this case, there is a deficiency in the motor neurotrophic hormone, normally released by 
postsynaptic cells and transported up from the presynaptic axon to the cell body, through retrograde 
transport (Kiernan et al., 2011). Studies performed by Dobrowolny and colleagues (2008) 
demonstrated that selective expression of mSOD1 in the muscle of a tg mouse provoked alterations 
and induced sings in the pre-symptomatic stage of ALS. Analysis of the  SOD1G93A mice showed 
how the ubiquitous expression causes first muscle atrophy, followed by the destruction of the NMJ, 
retrograde axonal degeneration and, ultimately, MN death (Dupuis and Loeffler, 2009). In 2010, Wong 
and Martin created tg mice expressing wt, human SOD1 G37R and human SOD1 G93A gene variants 
only in skeletal muscle. These tg mice developed age-related neurologic and pathologic phenotypes 
consistent with ALS, such as limb weakness and paresis with motor deficits.  
Muscle selective alterations in mitochondrial function might contribute to initiate NMJ 
dismantlement, followed by distal axonopathy, astrocytosis in the SC and MN loss in mice (Dupuis et 
al., 2009). Zhou and colleagues (2010b) reported alterations in mitochondrial inner membrane 
potential of muscle fibers near NMJ, in young SOD1 G93A mice, prior to disease onset. Finally, 
studies showed that inhibition of the pro-apoptotic machinery prevented MN loss in mice, but not 
denervation, neither promoted functional improvement or lifespan extension (Dewil et al., 2007a; 
Gould et al., 2006). 
 
2. Microglia in ALS: distinguishing between neuroprotective and neurotoxic 
properties  
 
2.1. Resting Microglia 
Microglia are the resident macrophage of the CNS, representing 10% of all cells in nervous 
system (Heneka et al., 2010). They are part of the innate immune response, participate in events 
associated with CNS organization, form the neuron-glia network and regulate the brain parenchyma 
homeostasis (Bessis et al., 2007; Moore and Thanos, 1996). Unlike the neurons and the other glial 
cells, microglia are not derived from neuroectoderm. Indeed, the original microglial population in the 
CNS differentiates from cells of the myeloid lineage that originate in the bone marrow and occurs early 
in embryonic development (Ransohoff and Perry, 2009). After accessing the CNS, microglia 
disseminate along the parenchyma and transform into the resting state (Heneka et al., 2010), term 
recently questioned once they are not inactive; in other words, they are continually surveying the 
surrounding environment by extending and retracting their processes (Davalos et al., 2005; 
Nimmerjahn et al., 2005). In this state, they acquire a ramified appearance, with thin processes 
extending from the cell body to the surrounding environment (Lull and Block, 2010), a morphology 
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seen in vivo but absent in cell cultures (Lull and Block, 2010). Each cell occupies a defined territorial 
domain, in order to avoid the overlap with neighboring microglia (Heneka et al., 2010). One question 
that remains unclear is if microglia can have a high level of self-renewal to support their population in 
both resting and activated states. When they are at a resting state the mitotic rate is low, but they can 
reach a high rate of proliferation when activated, suggesting they have leastwise a partial capacity to 
cell-turnover (Ajami et al., 2007; Lawson et al., 1992). 
Microglia differs from other populations of macrophages relatively to the expression of low 
levels of CD45 and major histocompatibility complexes (MHCs) and they are poor antigen presenting 
cells (APCs). One possible reason is the non-existence of serum proteins in the brain, which is 
responsible for macrophage activation (Lull and Block, 2010). Some in vitro experiments showed that 
resting microglia is responsible for the secretion of neurotrophic factors, such as insulin-like growth 
factor 1 (IGF1), BDNF, transforming growth factor-β (TGFβ) and NGF, as well as anti-inflammatory 
factors, such as IL-10 (Bessis et al., 2007; Polazzi and Monti, 2010), as represented in Figure I.4. 
They also have a phagocytic function, as it has been observed during neurogenesis. An elevated 
number of neuroblasts generated in subgranular zone of the dentate gyrus undergoes apoptosis, and 
functional microglia is able to phagocyte these apoptotic cells (Sierra et al., 2010). 
There are many mechanisms that maintain the resting state of microglia, most of them 
influenced by neurons. One of them is the signaling by CX3C-chemokine ligand (CX3CL1 or 
fractalkine) through its cell-surface receptor CX3CR1 on microglia, which restrains microglial cell 
activity (Saijo and Glass, 2011). In mice deficient in CX3CR1, it was observed deregulated microglia 
response, that further increased in experimental models of ALS (SOD1 G93A mice) and Parkinson’s 
disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), where a hyperactive 
microglial cell phenotype and a high neuronal loss was evidenced (Cardona et al., 2006).    
It was also reported by Ransohoff  and Cardona (2010) that signaling induced by the microglial 
cell receptors CD172, CD200R and CD45 following interaction with the neuronal cell-surface proteins 
CD47, CD200 and CD22, respectively, inhibit microglial cell activity (see Figure I.4). 
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Figure I.4 – Microglia can change their phenotype in response to a variety of insults. In the healthy central 
nervous system microglia are in a resting/vigilant state, characterized by ramified appearance with thin processes 
extending from the cell body to the surrounding environment. They secrete neurotrophic factors, such as insulin-
like growth factor-1 (IGF-1), brain-derived neurotrophic factor (BDNF), transforming growth factor-β (TGF-β) and 
nerve growth factor (NGF), as well as anti-inflammatory factors, such as interleukin-10 (IL-10). Motoneurons 
(MNs) influence the resting state of microglia through several mechanisms, such as the signaling by the CX3C-
chemokine ligand (CX3CL1 or fractalkine) through its cell-surface receptor CX3CR1. Signaling induced by the 
microglial cell receptors CD172, CD200R and CD45 following interaction with the neuronal cell-surface proteins 
CD47, CD200 and CD22, respectively, inhibit microglial cell activity. In response to a wide array of injurious 
stimuli, microglia undergo activation. They can acquire different activation states and, consequently, they produce 
substances that can be either beneficial or toxic to MN. M1 phenotype, or “classical activation”, which is cytotoxic 
in nature, describes a pro-inflammatory phenotype characterized by the production of interleukin-1β (IL-1β) and 
tumor necrosis factor-α (TNF-α), as well  increased release of reactive oxygen species (ROS) and nitric oxide 
(NO). M2 phenotype, or “alternative activation” refers to a phenotype capable of augmenting a neuroprotective 
environment, whose treatment with anti-inflammatory cytokines (e.g. IL-4 and IL-10), reduce the inflammation and 
lead to the release of neurotrophic factors, such as IGF-1 and glial-derived neurotrophic factor (GDNF), which 
promote neuronal outgrowth and support other glia. Another phenotype, occurring after a prolonged stimuli is 
called dystrophic or senescent microglia. Changes with ageing include dystrophic cytoplasmic processes 
characterized by slight enlargement, distinct loss of fine branches, and formation of cytoplasmic spheroids, 
gnarling, beading and fragmentation.  
 
2.2. Microglial Activation and function in the Healthy CNS 
In response to several insults, such as pathogen invasion, ischemia, abnormal protein content 
or altered neuronal activity, microglia suffer profound changes at the morphological, gene 
expression and functional levels, and switch into an active phenotype (Kettenmann et al., 2011), 
as represented in Figure I.4. Many endogenous and exogenous factors are released during insult. 
Chemokines, cytokines and components of the complement system, such as TNF-α, macrophage-
colony stimulating factor (M-CSF), (GM)-CSF, interferon gama (IFN), IL-1 and IL-6 are examples 
of endogenous factors, while LPS constitutes a good example of an exogenous factor (Dewil et 
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al., 2007a). As a consequence, microglia switch from a ramified to an amoeboid shape, with 
retraction and thickening of processes (Kreutzberg, 1996). They also become motile cells, moving 
to the damage local through chemotactic gradients and proliferate to increase local densities, 
ensuring more cells for the defense and restoration of homeostasis (Kettenmann et al., 2011). In 
this state, they acquire phagocytic features, in order to clean cellular debris resulting from 
apoptosis and normal cell death (Aloisi, 2001). Upon activation, microglia  produce factors that  
either  (i) induce repair and regeneration such as anti-inflammatory cytokines, neurotrophins and 
growth factors, (ii)  worsen neuronal injury such as ROS and pro-inflammatory factors and (iii) 
recruit and drive immune cell populations, including chemokines, immunogens, and 
proinflammatory factors, which promote the activation of the immune system (Block and Hong, 
2005). 
 
2.3. Neuroinflammation 
The inflammatory response occurs in response to environmental factors or subsequent to protein 
aggregation, enabling the intervention of innate and adaptive immune systems (Siegel et al., 2006). 
Although inflammation is linked to tissue repair processes and some inflammatory stimuli induce 
beneficial effects, such as phagocytosis of debris or apoptotic cells, it may determine an uncontrolled 
state characterized by the production of neurotoxic factors that will then amplify underlying disease 
mechanisms. Inflammatory response can also establish feed-forward loops, contributing to overwhelm 
normal resolution mechanisms (Glass et al., 2010). 
Neuroinflammation is characterized by the activation and proliferation of microglia, astrocytes and 
infiltrating T cells at sites of neuron injury, being now established as an important aspect of many 
neurodegenerative diseases, such as Parkinson’s disease, Alzheimer disease, and ALS (Glass et al., 
2010; Lewis et al., 2012). In what concerns to ALS, many studies found neuroinflammation in tg mice 
overexpressing variants of human mSOD1, which was associated with inherited ALS. A study in 
SOD1 G93A mice showed that astrocytic activation may exert a trophic influence on the MN, but is 
insufficiently conserved later on the disease course. Concerning microglial activation, it has been 
documented their contribution to the oxidative stress and damage involved in the disease process 
(Hall et al., 1998). Using the same model and applying cDNA microarray to monitor gene expression 
during neurodegeneration, Yoshihara and colleagues (2002) revealed an up-regulation of 
inflammatory genes related to glial cell activation at 11 weeks of age in the pre-symptomatic stage 
prior to MN death. In 2003, Hensley and collaborators (2003), using SOD1 G93A mice and a 
microglial cell line, showed that TNF-α was the principal driver for neuroinflammation, while several 
co-stimulating cytokines and chemokines act to potentiate TNF-α effects. 
  Studies with CSF from ALS patients revealed a deregulation of both anti- and pro-
inflammatory cytokines, as well as of growth factors, such as IL-6, IL-10 GM-CSF, VEGF and IFN-γ 
(Mitchell et al., 2009), suggesting the involvement of glial cells. On the contrary, when microglia 
proliferation was blocked through the ablation of TNF-α in mSOD1 mice, it was shown no effect on the 
rate of disease progression, placing in doubt that microglia contribute to neurodegeneration in ALS 
(Gowing et al., 2006). However, recently it was found that early microglia functional deficits precede 
ALS onset. Indeed, the Authors observed that the number of microglia in the SC of the mSOD1 mice 
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decrease at the pre-symptomatic age, although no changes on cell morphology were observed. 
Moreover, two sets of microglia (high and low expression of Iba1 cells) were observed at the early-
symptomatic age: increased population of Iba1high cells and decreased number of Iba1low microglia. 
This finding suggests an early participation of microglia in the initiation of ALS (Gerber et al., 2012).  
Many studies focused in T-reg cells, which have been shown to play a significant neuroprotective 
role through the modulation of neuroinflammation. Huang and Richard (2001) showed an increase of 
the chemokine (C-C motif) ligand 2 (CCL2), which is responsible for enhancing the trafficking of T cells 
into CNS. In adition, it was desmontrated that T cells play an endogenous neuroprotective role in ALS 
through the modulation of the trophic/cytotoxic balance of glia (Beers et al., 2008; Chiu et al., 2008). 
Others proposed that a reduction of T-reg cells in the blood of sALS patients might result from their 
recruitment from the periphery into the CNS, in order to activate resident innate immune cells such as 
microglia, as well as anti-inflammatory cytokines (Kipnis et al., 2004; Mantovani et al., 2009). 
 
2.3.1. Cell communication in response to inflammation 
A variety of surface receptors are also up-regulated in the activated microglia, including MHC, 
complement receptors (Liu and Hong, 2003) and pattern-recognition receptors (PRRs) which include 
toll like receptors (TLRs). MHC class II expression is important for the activation of naive T cells, 
suggesting the influence of microglia in activation of the adaptive immune system. Microglia operate 
as the primary sensors of pathogen-associated molecular patterns (PAMPs) in the CNS and express 
all TLRs (Saijo and Glass, 2011). For example, TLR4 is responsible for LPS recognition and 
consequent activation of caspase cascade and nuclear factor-κB (NF-κB) activation, triggering the 
production of neurotoxic pro-inflammatory mediators and NO (Burguillos et al., 2011), as represented 
in Figure I.5. Beyond PAMPS, TLRs also recognize endogenous damage-associated molecular 
patterns (DAMPs) provoked by metabolic products and molecules released by dead cells, as the high-
mobility group box 1 (HMGB1) (Chen and Nunez, 2010; Wang et al., 1999). A prolonged microglia 
activation of TLRs contributes to pathological ways of inflammation, which in turn mediate 
neurodegenerative diseases (Saijo and Glass, 2011). 
Beyond PRRs, other receptors are responsible for the recognition of DAMPs released from damage 
cells and are important in clearance of debris and in tissue repair. Receptor for advanced glycation 
end-products (RAGE) is the prototypic DAMP receptor (Sims et al., 2010). Microglia are also known to 
express both ionotropic receptors, such as the P2X1 to P2X7, and metabotropic receptors, such as 
P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11 to P2Y14, which bind purines or pyrimidines and activate 
downstream signaling cascades through G proteins. ATP mainly activates P2X receptors and induces 
the transcription of pro-inflammatory mediators (Saijo and Glass, 2011), as shown in Figure I.5 
Several molecules on the surface of apoptotic cells and corresponding receptors have been shown to 
be involved in the recognition and ingestion of apoptotic cells by microglia. For example, uridine 
diphosphate (UDP) released from dying neurons triggers microglial cell P2Y6 receptors and induces 
phagocytosis of the neurons (Koizumi et al., 2007), as we can see in Figure I.5 Another important 
molecule secreted by microglia and involved in phagocytosis is Milk Fat Globule Factor-E8 (MFG-E8). 
It works as a bridge to attach the phagocytic cell to the apoptotic cell, through the recognition of 
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phosphatidylserine located at the outer membranes of cells suffering apoptosis. After that recognition, 
a signaling cascade response in microglia is triggered, stimulating the  phagocytosis of the dying cell 
(Liu et al., 2013). Moreover, certain caspases, for example caspase-1, also play a pivotal role in 
immune-mediated inflammation. Necrotic and apoptotic cell death is known to release nuclear 
proteins, such as HMGB1 and histones. Both are known to amplify the lethal condition of LPS-
mediated sepsis in animals. RAGE, together with TLR2 and TLR4, is triggered by HMGB1 and 
activates the transcription of pro-inflammatory genes in microglia (Erlandsson Harris and Andersson 
2004; Sims et al. 2010), as represented in Figure I.5. 
Indeed, importance of HMGB1 has risen, in respect to its role in inflammation and immunity. It 
is a ubiquitous nuclear protein present in almost all cell types. Beyond its function as a nuclear 
cofactor in transcription regulation, it can be extracellularly released, where it mediates activation of 
innate immune responses, including chemotaxis and cytokine release.  It is passively released by 
necrotic cells and actively secreted by stimulated monocytes/macrophages and astrocytes, binding to 
the RAGE and other receptors, including TLR2 and TLR4 (Yang et al., 2013). Evidence suggests a 
contribution of HMGB1 in many inflammatory diseases, which may be a key point to consider in ALS 
pathophysiology. In the SC of SOD1 G93A mice a reduction of HMGB1 has been observed in 
degenerating neurons during the progression of the disease, whereas reactive glial cells displayed 
HMGB1 in the nucleus, but not in the cytosol (Lo Coco et al., 2007). On the contrary, another study on 
human tissue (end stage of disease) did not detect a significant change in the number of MN showing 
nuclear and/or cytoplasmic staining in ALS SC. However, cytoplasmic translocation of HMGB1 in 
activated microglia and astrocytes were observed, supporting the role of glial cells as major source of 
extracellular HMGB1 in ALS patients, with both rapid and slow disease progression (Casula et al., 
2011). 
Matrix metalloproteinases- 9 and 2 (respectively, MMP-9 and MMP-2) are gelatinases responsible 
for extracellular matrix degradation and are also implicated in inflammation. Secretion by microglia in 
the context of neuroinflammation is involved in the recruitment of T-lymphocytes to CNS (Nagase et 
al., 2006). The main cellular sources of MMP-2 in the brain are microglia and vascular endothelium 
and its increased production may lead to damage in white matter myelin and microvascular beds 
remodelation (Ihara et al., 2001). MMP-9 has been associated to synaptic plasticity, learning, and 
memory (Wilczynski et al., 2008). Interestingly abnormally high amount of MMP-9 was found in the 
motor cortex, as well as thoracic and lumbar cord specimens from ALS patients (Lim et al., 1996). 
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Figure I.5 – Microglia-neuron cross-talk during inflammatory process. Many disease-associated factors are 
responsible for microglia activation, through pattern-recognition receptors (PRRs), which include toll like receptors 
(TLR) and receptor for advanced glycation end-products (RAGE), and purinergic receptors (P2X and P2Y), all 
implicated in  M1-activated  microglia  phenotype. These factors include recognize pathogen-associated 
molecular patterns (PAMPs) such as lipopolysaccharide (LPS), damage-associated molecular patterns (DAMPs) 
such as high-mobility group box 1 protein (HMGB1), ATP and uridine diphosphate (UDP), and neurodegenerative 
disease-specific protein aggregates, such as superoxide dismutase 1 (SOD1) aggregates. The presence of SOD1 
aggregates and the increase of reactive oxygen species (ROS) in the injured motoneurons (MNs) induce 
apoptosis. One of the molecules released by these MN is HMGB1, which binds to TLR-2, TLR-4 and RAGE 
receptors, all present in microglia. Consequently, NF-B-mediated gene transcription is activated, leading to the 
production of interleukin-1 beta (IL-1β), IL-6 and tumor necrosis factor alpha (TNF-α). ATP released by injured 
MN binds to P2X7 receptor in microglia and also induces the transcription of pro-inflammatory mediators. UDP 
released from dying neurons triggers microglial cell P2Y6 receptors and induces phagocytosis of the MN. 
Activated microglial cells release nitric oxide (NO) through the inducible nitric oxide synthase (iNOS) activation, as 
well as reactive oxygen species (ROS) produced by nicotinamide adenine dinucleotide phosphate-oxidase 
(NADPH), which contribute to neuroinflammation. 
 
2.4. Defining microglial activation 
Activated microglia produce substances that can be either beneficial or toxic to neurons, 
depending on the phenotypes (Saijo and Glass, 2011). The degree of inflammatory output from 
microglia is tightly regulated by both intrinsic factors, as well as by cross-talk between neurons and 
glia (Streit, 2002).  
M1 phenotype, or “classical activation”, which is cytotoxic in nature, describes a proinflammatory 
phenotype characterized by the production of IL-1β and TNF-α, and increased release of ROS and NO 
through the up-regulation of NADPH oxidase and iNOS (Henkel et al., 2009), as represented in Figure 
I.4. Their activation and proliferation are influenced by IFN-γ and GM-CSF produced by Th1 
lymphocytes and by infiltrating neutrophils (Mosser and Edwards, 2008) and  by signaling through 
TLRs (Glass et al., 2010). In vitro co-cultured microglia and neurons, LPS activated TLR4 and 
provoked increased microglial production of NO and ROS, as well as increased levels of extracellular 
glutamate, which culminates in the excitotoxic death of neurons (Ajami et al., 2007).  
M2 phenotype, or “alternative activation” describes a phenotype capable of augmenting a 
neuroprotective environment. Treatment with anti-inflammatory cytokines (e.g. IL-4 and IL-10) reduces 
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the inflammation (Martinez et al., 2006) and leads to the release of neurotrophic factors, such as IGF-
1 and GDNF, which promote neuronal outgrowth and support other glia (Isgaard et al., 2007), as 
shown in Figure I.4. The metabolism of L-arginine also allows the distinction between  M1 and M2 
activation features: in M1-activated macrophages and microglia, the up-regulation of inducible nitric 
oxide synthase (iNOS) converts L-arginine to L-citrulline (with consequent activation of NOS), while in 
M2-activated macrophages and microglia it converts L-arginine to L-ornithine (Mildner et al., 2007). 
 
2.5. Role of microglia activation in ALS 
The effects of activation and proliferation of microglia in ALS are reported in various studies and a 
significant MN loss are seen in specific areas, such as the motor cortex, motor nuclei of the brainstem, 
the corticospinal tract and the ventral horn of the SC (Ince et al., 1996; Kawamata et al., 1992). 
Activation of microglia is found even in areas of only mild degeneration (Ince et al., 1996). Studies 
showed an increase of many factors usually present in microglia activation, such as M-CSF 
expression, which is up-regulated in ALS pre-central gyrus (Akiyama et al., 1994) and TNF-α levels in 
ALS serum of ALS patients (Poloni et al., 2000). In general, an increased expression of pro-
inflammatory cytokines is found in the CSF from ALS patients (Sekizawa et al., 1998). Furthermore, 
cyclooxygenase-2 (COX-2) expression is enhanced in mSOD1 mice (Almer et al., 2001). Many of 
these findings were observed in both the mSOD1 mice and rat in the presymptomatic phase, with a 
constant microglial response, observed during the active phase of the disease progression (Alexianu 
et al., 2001; Elliott, 2001; Hensley et al., 2003; Xie et al., 2004). IL-1β, a cytokine released by microglia 
at the M1 stage was found increased in SOD1 G93A mice (Meissner et al., 2010) and related to a 
disease acceleration (Nguyen et al., 2001). Indeed, the administration of IL-1 receptor antagonist 
prevented disease progression in mice. However studies using SOD1 G37R mice in a context of  IL-
1β knock-out showed no alteration of the disease course, neither any compensatory mechanisms by 
other cytokines (Nguyen et al., 2001). In another study, it was observed increased COX-2 mRNA and 
protein levels in  SC samples from  ALS patients, paralleled by increased prostaglandin E2 (PGE2) 
content in CSF at regions associated with MN pathology (Maihofner et al., 2003). Excessively 
activated microglia also seems to provoke MN death, through the release of free radicals, which 
augment the susceptibility of the MN AMPA/kainate receptor to the toxic effects of glutamate (Zhao et 
al., 2004).  On the other hand, MN death was suppressed by COX-2 inhibition, avoiding chronic 
glutamate excitotoxicity in organotypic SC system (Drachman and Rothstein, 2000). Furthermore, 
Turner and colleagues (2004) detected activated microglia in prefrontal cortex,  motor cortex,  
thalamus and  pons of ALS patients by histological studies of post-mortem brains and SC tissue using 
the PET ligand PK1195, which labels the peripheral benzodiazepine receptor that is expressed by 
activated microglia. 
The products of activated microglia could lead to MN death via Fas ligand or NO-induced 
apoptotic pathways (Raoul et al., 2002), and/or by TNF-α-mediated apoptotic mechanisms (He et al., 
2002), whose mechanisms in detail are represented in Figure I.6. Moreover, up-regulation of p38 
MAPK pathway that mediates microglial activation (Koistinaho and Koistinaho, 2002) and down-
regulation of the anti-apoptotic Akt pathway (Dewil et al., 2007b), have been described in ALS. 
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About microglial priming, studies using models of MN degeneration, showed that it happens 
before or concominant with the onset of clinical disease. In fact, it was shown that activation and 
proliferation of microglia begins during early pre-symptomatic stages of the disease (Alexianu et al., 
2001). In chimeric mice the survival of MN injury is influenced by the extension of non-neuronal cells 
expressing the mutant transgene. Moreover, non-tg MN surrounded by glia expressing mSOD1 
evidenced to degenerate, while tg MN surrounded by non-tg glia remained healthy (Clement et al., 
2003). To support this study, the genetic knock-down of mSOD1 in cells of the macrophage lineage 
significantly reduced the progression of ALS (Weydt et al., 2005). In addition, chronic administration of 
LPS in mSOD1 mice resulted in an exacerbated microglial activation, which consequently contributed 
to disease progression (Nguyen et al., 2004). 
There are several signaling molecules that can also play a role in neuronal-glial cross-talk 
impairment in ALS. As previously mentioned, fractalkine and CD200 produced by neurons prevent 
microglia from becoming neurotoxic. Knockout of CX3CR1 showed a deregulated microglia response 
and an increased cell-autonomous toxicity; however the addition of mSOD1 increased microglial 
activation and promoted MN death (Cardona et al., 2006; Hoek et al., 2000). MMPs may also have an 
important role in cell-to-cell communication. MMP-2 and, mostly MMP-9 expression was found to be 
elevated in the SC of SOD1G93A mice (Fang et al., 2010). Increased expression of NO and ROS was 
also observed in patients and rodent models, leading to lipid peroxidation and protein carbonylation, 
which disrupt the integrity and function of neurons and glial cells (Beers et al., 2006; Wu et al., 2006). 
On the other hand, Kiaei and colleagues (2007) found that the lack of MMP-9 increased the survival of 
SOD1 G93A mice and the neurotoxicity induced by their presence was suggested to be mediated 
through the up-regulation of neuronal TNF-α and FasL expression and activation.  
All these studies point to the relevance of the activated tg microglia in the spread of the MN 
neurodegeneration. Interestingly, activated microglia might also have a neuroprotection function, since 
Chiu and colleagues (2008), demonstrated that the expression of the neurotrophic factor IGF-1 and 
anti-inflammatory IL-1R antagonist by microglia increased with disease progression. In addition, no 
changes in TNF-α levels were detected with disease progression, although an increase of IL-1β, TNF-
α and NADPH oxidase was obtained in the disease end-stage (Beers et al., 2011). These 
observations may suggest that, during initial stages of the disease in the mSOD mice, microglia 
appear to exhibit an M2 phenotype, thus supporting neuronal survival. However, as the disease 
progress, microglia shift towards an M1 phenotype, although the physiological mechanisms that 
provoke such activation have not yet been elucidated.  
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Figure I.6 – Signaling mechanisms involved in neuron-microglia cross-talk impairment in Amyotrophic 
Lateral Sclerosis. Inflamma-drivers released by  activated microglia may lead to motoneurons (MN) death via 
Fas ligand (FasL),  NO-induced apoptotic pathways and tumor necrosis factor-α (TNF-α)-mediated apoptotic 
mechanisms. FasL also released by microglia in such conditions binds to its receptor (FasR) in the injured MN 
and recruits the adaptor molecule Fas-Associated protein with Death Domain (FADD). Subsequently, caspase-8 
is activated, leading to the activation of caspase cascade, which culminate in apoptosis. Fas-R can also bind to 
Death-Associated protein (Daxx), which activates mitogen-activated protein (MAP) kinase 38 and neuronal nitric 
oxide synthase (nNOS). Consequently, NO production increases and their reaction with the anion superoxide (O2.-
) contributes to a high production of peroxinitrite (ONOO-), a powerful reactive oxidant that triggers cell death. NO 
may also be produced by activated microglia, becoming a contributor for NO-induced apoptosis. TNF-α released 
by microglia binds to its receptor (TNF-R1) in the injured MNs and, like Fas L, triggers cell death through FADD 
activation. TNF-α released by microglia and reactive oxygen species (ROS) present in injured MN constitute a 
potent transcriptional activator of metalloproteinase-9 (MMP-9), an enzyme involved in extracellular matrix 
degradation. 
 
3. Different models for the study of neurodegeneration in ALS 
Acquired knowledge about cellular and molecular pathophysiological mechanisms of 
neurodegenerative diseases is crucial to allow the development of novel therapeutic strategies. For 
this, creation and use of experimental models is essential to perform studies in vivo and in vitro. In 
vitro models rely on cell cultures, slices or organotypic cultures bring us information about cellular and 
molecular pathophysiological mechanisms of the disease, as well as about cellular communication 
failure. In vivo models, usually  rodents, allow an approximation to the features involved in human 
disease (Tovar et al., 2009). The variety of in vitro and in vivo models for the study of ALS 
pathogenesis is huge. However, in the next section we will be only focusing in the experimental 
approaches used in the work developed and here presented.    
 
3.1. In vitro models 
3.1.1. Primary cultures of MN 
Primary SC cultures were established to study morphological, biochemical and 
electrophysiological characteristics of MN (Ransom et al., 1977). The SCs are obtained  from 12-14 
days-old rodent embryos because it is easy to access and remove; then, the SC is dissociated by 
mechanical and enzymatic procedures, and plated on matrix-coated dishes (Tovar et al., 2009). MN, 
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astrocytes and microglia can be extracted, purified and maintained in culture with high viability yields 
(Gingras et al., 2007). MN are easy to identify in culture, once they have a large size (up to 20 µm in 
diameter), dendritic trees and may be stained for the transcription factor Hb9 and choline 
acetyltransferase, which are  specific markers of MN (Gingras et al., 2007; Tradewell et al., 2011). MN 
are present in very small quantities, so they are dependent of the presence of glial cells to perform 
trophic support. If absent, the culture only lasts for 2 weeks (Bar, 2000; Lunn et al., 2009).  
This type of culture is useful to study effects of long-term cell survival in ALS, once they can 
be maintained in culture for up to 7 weeks (Tradewell et al., 2011). Purified MN can also be cultured 
on an astrocyte feeder layer for several weeks to display characteristics  similar  to adult MN (Bar, 
2000). MN can also be induced to express multiple copies of the gene of interest, in this case mSOD1, 
by microinjection of vectors directly into the cells (Tradewell et al., 2011; Tradewell and Durham, 
2010). This type of culture was used to demonstrate that MNs are vulnerable to glutamatergic 
excitotoxicity through AMPA receptors (Rao et al., 2003). 
However, the conditions of the cells in culture cannot mimic in vivo environment, once the 
complex interactions developed in the nervous system are lost and, consequently, some results 
obtained in vitro may not be reproducible in vivo. Finally, in these cultures it is not possible to express 
some features of the adult phenotype, once primary cells are derived from embryos (Park et al., 2004). 
 
3.1.2. NSC-34 and N9 Cell line: assembly of mixed culture  
Immortalized and clonally uniform murine NSC hybrid cell lines were developed to dissect MN 
biology in vitro. All NSC hybrids were produced through somatic fusion between the N18TG2 
aminopterin-sensitive neuroblastoma and SC MN from enriched primary cultures (Cashman et al., 
1992). They are composed by small undifferentiated and proliferative cells and large multinucleate 
cells. This cell line contains small proliferative and undifferentiated cells and larger multinucleate cells. 
Characteristics of MN relate to acetylcholine synthesis, storage and release, generation of action 
potential, expression of neurofilament proteins and association with neuromuscular synapse-specific 
basal lamina glycoproteins (Tovar et al., 2009). They respond to agents affecting voltage-gated ion 
channels, organization of cytoskeleton and axonal transport, similarly to primary MN, although they 
failed in reproducing synaptic connections when at the undifferentiated  stage (Durham et al., 1993). 
This cell line expressing human mSOD1 by transfection with a plasmid is considered a cellular model 
of ALS and revealed  similar features to those  of MN degeneration in ALS, like fragmentation of the 
Golgi apparatus (Gomes et al., 2008), mitochondrial deregulation (Raimondi et al., 2006) and ER 
stress (Vijayalakshmi et al., 2011), among others. A big problem resides on the characteristics of the 
neuroblastoma lineage that these cell lines retain, mediated by the oncogene N-myc involved in cell 
proliferation. Therefore, interference on the mechanisms of neuronal death and its prevention by 
possible therapeutic agents, cannot be discarded (Tovar et al., 2009). 
N9 is a microglia cell line derived from mouse brain that shares many phenotypical features 
with primary mouse microglia. However, the modified cell has an increased proliferation and 
adherence capacities (Stansley et al., 2012). N9 microglia cells arose from the immortalizing primary 
microglia cells with the v-myc or v-mil oncogenes of the avian retrovirus MH2 (Righi et al., 1989). Zhao 
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and colleagues (2011) demonstrated that LPS increased iROS production and the expression of 
gp91phox in N9 microglial cells. Consequently, intracellular ROS can activate diverse downstream 
signaling molecules such as protein kinase C, MAPK and NF-κB to regulate the expression of genes 
encoding a variety of pro-inflammatory factors (Zhao et al., 2011).  
Mixed cultures with these two cell types are good candidates to get a suitable model to study 
the mechanisms involved in neurodegeneration and the specific dialogue of MN with microglia in the 
pathogenesis of ALS. In fact, it was recently demonstrated that differentiated NSC-34 transfected with 
human SOD1G93A have increased mitochondrial dysfunction, apoptosis and efflux of neuro-
inflammatory markers such as MMP-9 and NO, features of ALS pathogenesis.  
 
3.1.3. Organotypic cultures  
Organotypic cultures consist in  tissue slices cultivated in air-liquid interface which unlike cell 
lines, allow to preserve all the cellular content and the complex electrophysiological and biochemical 
organization of cells in the SC, as a 3D system (Tovar et al., 2009). The slices can be obtained from 
both embryos and postnatal animals, namely from mutated mice, whose genotype has to be identified 
after birth (Mazzone and Nistri, 2011). After dissection of the lumbar SC and removal of the meninges, 
transversal sections with 200-400 μm are separated and transferred into membrane inserts fitting six-
well or 12-well culture plates (Caldero et al., 2010), where they can be kept in culture for more than 2 
months. These type of culture maintain the choline acetyltransferase and acetylcholinesterase 
activities (Delfs et al., 1989). 
These  models allow dynamic studies with many drugs but it cannot reproduce entirely what 
happens in an in vivo system and much less in the ALS patient (Tovar et al., 2009). Here, MN 
degeneration can be induced by chronic exposure to the glutamate transporter blocker threo-β-
hydroxyaspartate (THA) (Rothstein et al., 1993), kainate (Mazzone and Nistri, 2011) or lithium 
(Caldero et al., 2010).  
 
3.2. In vivo models 
3.2.1. Transgenic mSOD1 rodents 
As previously mentioned, approximately 20% of fALS cases are due to mSOD1. Therefore, 
Gurney et al. created mice that express human mSOD1 (Gurney et al., 1994). The first mutations 
produced were the substitution of glycine for alanine at position 93 (G93A) and of alanine for valine at 
position 4 (A4V). Other SOD1 mutations have been subsequently overexpressed in tg mice, such as 
G37R, G86R, and D90A mSOD1 proteins, all leading  to MN degeneration (Borchelt et al., 1994; 
Jonsson et al., 2006; Ripps et al., 1995) .  
Phenotypically, the symptom age onset and its  severity is directly proportional to the amount of 
SOD1 expressed in the tissue, supporting the hypothesis of gain of toxic function of mSOD1 (Gurney, 
2000). Expression of different SOD1 gene mutations leads to different biochemical properties in tg 
mice, even in the presence of endogenous mSOD1 gene, triggering the development of a 
neurodegenerative disease similar to the human illness (Ripps et al., 1995).  
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The disease in tg mice begins with hind limb limitation, impaired leg extension and reduced stride 
length, and continues to complete paralysis of the limbs within few days (Gurney et al., 1994).  Cellular 
alterations include vacuolar deterioration of MN and their processes at early stages, followed by 
neuronal loss and atrophy of the ventral horns in the SC at a late stage; another regions beyond SC 
could be affected, such as medulla, pons and midbrain (Dal Canto and Gurney, 1995). Specifically in 
SOD1 G93A SJL mice, the pre-symptomatic stage of motor dysfunction begins at six week of age and 
symptomatic stage develops at 13 weeks of age, which culminate with death at 4-5 months of age 
(Martin et al., 2005). All of these characteristics are also seen in tg rats (Howland et al., 2002; Nagai et 
al., 2001). 
However, it has been difficult to match the findings made in this model with the processes 
occurring in patients that do not have mutations in SOD1 (Dupuis et al., 2004). This model also fails in 
the evaluation of  drugs that showed  therapeutic efficacy, due to  the small number of animals usually 
evaluated, the lack of randomization and the initiation of the treatment before symptoms onset 
(Benatar, 2007; Scott et al., 2008). 
 
4. Recent findings on diagnosis and therapeutic approaches in ALS 
Diagnosis in ALS is based on diagnostic criteria, called El Escorial criteria and more recently the 
Awaji criteria, which present good sensitivity and specificity. These criteria uses neurophysiological 
data acquired by electromyography (EMG) together  with the clinical information (Kiernan et al., 2011). 
It can also include other three key principles: evidence of LMN loss, evidence of reinnervation and 
fibrillation and sharp waves or fasciculation potentials. Using these criteria, it is possible to classify the 
patient into groups of clinically definite, clinically probable, or clinically possible ALS (Costa et al., 
2012).  Magnetic resonance imaging (MRI) scan may be also used to rule out any (SC) or brainstem 
disease. Blood tests are important to detect abnormal proteins or hormone levels, or even the 
presence of heavy metals such as lead more closely associated with other neurological diseases. The 
CSF analysis should be done in parallel to evaluate the existence of other abnormalities (e.g., viral, 
autoimmune, neurotoxic). Recently, metabolomics profile in the CSF was demonstrated to have 
different signatures between ALS patients with mutations and those without mutations (Wuolikainen et 
al., 2012). Genetic testing for mSOD1 also exists, but little information can be given to the patient 
since  the majority of families with fALS (80%) do not have alterations in their SOD1 gene (Naganska 
and Matyja, 2011). 
Despite the advances in the comprehension of the mechanisms that trigger 
neurodegeneration in ALS, there is not an effective therapeutic for this disease. Actual therapeutic 
strategies being developed use pharmacotherapy, physical therapy, gene therapy, stem-cell therapy, 
RNA therapy and immunotherapy areas. 
By now, Riluzole is the only drug approved by the Food and Drug Administration for the 
treatment of ALS and its function is to decrease the release of glutamate (Bensimon et al., 1994). It 
does not reduce MN damage, but two therapeutic trials showed that the drug prolonged survival by 3-
6 months (Bensimon et al., 1994; Lacomblez et al., 1996).  
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Many clinical trials also tried other neuroprotective agents, such as Memantine, Tamoxifen, 
Ceftriaxone, Creatine, Myotrophin®, Celebrex, Neurodex, Oxandrolone, CoQ10, Topiramate, 
Xaliproden, Indinavir, Minocycline, Buspiron, Gabapentin, α-tocopherol, among others (Desnuelle et 
al., 2001; Gordon, 2005; Miller et al., 2001; Phukan and Hardiman, 2009), but none of them has 
succeeded for treatment in ALS patients. 
Citicoline, also called CDP-choline (cytidine-5- diphosphocholine) is an endogenous 
nucleoside that has neuroprotective properties related to its action on glutamate-mediated cell death. 
Studies using organotypic cultures of the rat lumbar SC showed a decrease of the extracellular levels 
of glutamate, by inhibition of neuronal glutamate efflux and an increased astrocytic glutamate uptake 
(Matyja et al., 2008). Another compound involved in the apoptotic mechanism of cell death is 
Erytropoietin (EPO). Many studies showed that EPO promote neuronal survival, when exposed with 
damaging agents through antagonizing glutamate cytotoxic action, enhancing antioxidant enzyme 
expression, reducing the free radical production rate and affecting neurotransmitter release (Grasso et 
al., 2007; Liu et al., 2008).  
Immunotherapy focuses in the protection and regeneration of the immune system, through 
appliance of intravenous immunoglobulins and experimental treatment with vaccination, minocycline, 
neurotrophic factors and antibodies. Several immunosuppressive and immunomodulatory therapies 
have been tried in ALS but with no success (Calvo et al., 2010). The most studied is minocycline, a 
second-generation tetracycline with distinct antibiotic and anti-inflammatory properties (Whiteman and 
Halliwell, 1997). Their neuroprotective effects result from the inhibition of microglial activation (Tikka et 
al., 2001) and possibly proliferation (Tikka et al., 2002). The studies passed in phase I/II in ALS 
patients, but no difference between treated and untreated groups was observed (Gordon et al., 2004). 
More recently, attention has been given to stem cell transplantation, which consists in 
restoration of motor function, by introducing human stem cells into the SC to replace degenerating MN 
(Rowland and Shneider, 2001). The treatment may stop or slow the progression of MN disease, 
providing growth factors, immunomodulation of injurious lesion  environment and anti-inflammatory 
effects on microglia and astrocytes (Traub et al., 2011). However, in ALS, this treatment is difficult due 
to the complexity of the pathways involved in motor function (Rowland and Shneider, 2001). 
Nevertheless, several stem cell sources have been studied in ALS, including bone marrow 
transplantation (Corti et al., 2010; Ohnishi et al., 2009), mesenchymal stem cell (MSC) transplantation 
(Mazzini et al., 2010; Vercelli et al., 2008), neural stem cell transplantation (Corti et al., 2007; Xu et al., 
2006) and induced pluripotent stem cells (iPSCs) (Ebert et al., 2009), with promising results. Vercelli 
and colleagues (2008) transplanted human MSCs into the lumbar SC of asymptomatic SOD1G93A 
mice and proved that these type of stem cells are a good candidate for ALS cell therapy, since they 
can survive and migrate after transplantation in the lumbar SC, while preventing astrogliosis and 
microgliosis. Zhou and colleagues (2013) showed that intrathecally transplanted human marrow 
stromal cells inhibited inflammatory response in mSOD1 mice, evidenced by a reduction in microglial 
activation, TNF-α secretion and iNOS protein expression.   
Gene therapy consists to the usage of a vector, most commonly viral, to deliver the 
therapeutic gene of interest to the affected region or tissue (O'Connor and Boulis, 2012). Vaccines that 
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target SOD1G93A have been developed and have shown to be effective in mouse models of ALS 
(Takeuchi et al., 2010). It was also implemented a SOD1 gene-silencing approach, which may be 
useful to delay disease onset or progression (Smith et al., 2006). 
RNA interference therapy consists in the inhibition and regulation of gene expression through 
the binding of a noncoding miRNA in mRNA. It is very useful in autosomal-dominant diseases, where 
the silencing of the dominant mutant allele might cure the patient (Traub et al., 2011). Several studies 
have demonstrated effective mSOD1 silencing and improved motor outcomes in mice (Ralph et al., 
2005; Raoul et al., 2005). miR-155 has shown to be an excellent therapeutic target derived from its 
abundance and marked elevation in ALS, together with its reproducibility across species and various 
ALS models, as well as prior work linking miR-155 with immunity and inflammation. Recent data 
suggest that miR-155 is increased in peripheral monocytes from ALS-model mice and ALS patients, 
suggesting that modulation of these cells may be a potential therapeutic approach (Butovsky et al., 
2012).  
For all the reasons mentioned in this chapter, microglia is now seen as a possible therapeutic 
target for ALS disease and studies involving transplantation of wt microglia seems to provide a 
promising approach.  
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AIMS 
 
The main goal of this thesis is to explore the role of microglia in preventing or restoring 
motoneurons (MNs) function in ALS, through the evaluation of signaling molecules that may be 
involved in cellular cross-talk, by using two different experimental models: (i) mixed MN-microglial 
cultures (NSC-34-N9 cell lines); (ii) organotypical slices from mice spinal cord. Parameters to be 
evaluated will include SOD1 accumulation, oxidative stress markers (glutamate and ATP) and 
inflammatory mediators (nitric oxide, metalloproteinases, toll-like receptor-4 and high mobility group 
box 1). 
 
More specifically, the aims are:  
 
i. Optimization of mixed cultures, composed by MN-like cell line (NSC-34) and microglial cell line 
(N9). For this, we will use a MN-like cell line expressing human-SOD1 with G93A mutation 
(NSC-34/hSOD1G93A) and the microglial cell line N9. NSC-34 expressing human-SOD1wt 
will be used as controls. To produce a mixed culture, we will add N9 cells to mutated MNs at 0 
and 2 days-of-differentiation (DIV) and cells will be maintained in cultures for 4 and 7 DIV.  
 
ii. To set-up and characterize organotypic cultures obtained from lumbar spinal cord (SC) of 
ALS-transgenic mice carrying the same human SOD1 mutation (TgSOD1-G93A mice). 
Response to SOD1 accumulation and to LPS immunostimulatory stimulus will be evaluated to 
assess the validity of the culture and a more integrative cellular participation in the 
pathophysiological mechanisms of ALS. Moreover, it will be a suitable ALS model to test the 
efficacy of novel therapeutic compounds to halt, or at least delay, ALS progression. 
 
 
The final purpose of this thesis project is to provide insights into microglia and inflammatory 
mediators as players in the onset and progression of ALS and to establish a SC organotypic culture as 
resource for future studies on neuroinflammation-neurodegeneration and on drug prevention effects.  
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II: MATERIALS AND METHODS 
 
 
 
 
1. Materials 
1.1 Chemicals  
 
Dulbecco’s modified Eagle’s medium-Ham’s F12 medium (DMEM-Ham´s F-12), DMEM high 
glucose w/o pyruvate, fetal bovine serum (FBS), Penicillin/Streptomycin, L-glutamine and non-
essential aminoacids (NEAA) were purchased from Biochrom AG (Berlin, Germany); Hank’s balanced 
salt solution (HBSS) without phenol red (1x), B-27® Serum-Free Supplement (50X) and Neurobasal 
medium (1x) were acquired from GIBCO® (Life Technologies, Inc.,Grand Islands, USA); Roswell Park 
Memorial Institute (RPMI) 1640 medium, trypsin-Ethylenediamine tetraacetic acid (trypsin-EDTA)  
solution (1X), ATP, β-Nicotinamide adenine dinucleotide 2′-phosphate (NADP+), bovine serum albumin 
(BSA), Coomassie Brilliant Blue R-250, naphtylethylenediamine (C12H14N2), sulfanilamide 
(C6H8N2O2S), Tris-base, phenylmethylsulfonyl fluoride (PMSF), Poly-D-Lysine (PDL) and β-
mercaptoethanol were purchased from Sigma-Aldrich (St. Louis, MO, USA); Geneticin sulfate (G418) 
and nonyl phenoxypolyethoxylethanol (NP-40) were obtained from Calbiochem (Darmstadt, 
Germany); L-glutamic acid kit, Triton X-100, glucose-6-phosphate dehydrogenase, hexokinase and 
protease inhibitor cocktail tablets  were obtained from Roche Diagnostics (Mannhein, Germany);  
Nitrocellulose membrane was obtained from Amersham Biosciences (Piscataway, NJ, USA); sodium 
dodecyl sulphate (SDS) was acquired from VWR-Prolabo; cell lysis buffer® and LumiGLO® were from 
Cell Signaling (Beverly, MA, USA); acrylamide, bis-acrylamide, glucose anhydre, Tween 20, glycerol, 
absolute ethanol, acetic acid, sodium chloride (NaCl), potassium hydroxide (KOH), Gelatine, calcium 
choride (CaCl2) and perchloric acid (70%) were obtained from Merck (Darmstadt, Germany); Bio-
Rad’s Protein Assay Reagent was obtained from BioRad Laboratories (Hercules, CA, USA). All the 
other common chemicals were of analytical grade and were purchased either from Sigma-Aldrich or 
Merck. 
 
1.2 Antibodies  
 
Primary antibodies: Rabbit polyclonal anti-superoxide dismutase 1 (SOD1) and rabbit 
polyclonal anti-toll-like receptor 4 (TLR4) were purchased from Santa Cruz Biotechnology® (Santa 
Cruz, CA, USA). Mouse monoclonal anti-high mobility group protein B1 (HMGB1) was acquired from 
BioLegend® (San Diego, CA, USA). Mouse anti-β-actin was obtained from Sigma-Aldrich (St. Louis, 
MO, USA). 
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Secondary antibodies: Horseradish peroxidase-labelled goat anti-rabbit IgG was purchased 
from Santa Cruz Biotechonlogy® (Santa Cruz, CA, USA). Horseradish peroxidase-labelled goat anti-
mouse IgG was obtained from Amersham Biosciences (Piscataway, NJ, USA). 
 
1.3 Equipment  
Optical microscope with phase-contrast equipment [Olympus, model CK2-TR, purchased from 
Carl Zeiss, Inc. (North America)] were used for cell morphologic evaluation. Mini-PROTEAN Tetra cell 
system used for Western Blot and zymography was from Bio-Rad (Hercules, CA, USA). Microplate 
reader (PR 2100) was also from Bio-Rad and it was used for spectrophotometric measurements of 
protein, nitrites and glutamate content. GloMax® Multi Detection System (Sunnyvale, CA, USA) was 
used for ATP quantification. For metalloproteinases gel photographs and immunodetection in 
nitrocellulose membranes it was used ChemiDocTM equipment, also from Bio-Rad Laboratories. 
Sonication of samples was performed in the Ultrasonic Processor UP100H (Hielscher-Ultrasound 
Technology, Teltow, Germany). To ensure a stable environment to optimal cell growth (37°C and 5% 
CO2), cell cultures were maintained in HERAcell 150 incubators (Thermo Scientific, Waltham, MA, 
USA) and the work performed in sterile conditions in a HoltenLamin Air HVR 2460 (Allerod, Denmark). 
Eppendorf 580R (Eppendrof, Hamburg, Germany) and a Sigma 3K30 centrifuges were used for 
different experimental procedures. To slice tissue in organotypic cultures, it was used McIlwain Tissue 
Chopper (Gomshall, Surrey, UK). In other procedures, were used surgical material and the 
Stereomicroscope Stemi DV 4 [Carl Zeiss, Inc. (North America)]. 
.  
2. Methods 
 
2.1. In vitro mixed cultures  
For in vitro studies, were used two cell lines: NSC-34 and N9. NSC-34 is a murine neuroblastoma 
and spinal cord hybrid cell line that has many of the unique morphological and physiological 
characteristics of motoneurons (Cashman et al., 1992), as mentioned in the introduction. N9 cell line 
was developed by immortalizing primary microglia cells obtained from CD1 mouse cortex (Righi et al., 
1989). 
 
2.1.1. NSC-34 cell line 
NSC-34 cell line transfected with human SOD1, either wild type or mutated in G93A (NSC-
34/hSOD1wt or NSC-34/hSOD1G93A, respectively), were a gift from Júlia Costa, Instituto de 
Tecnologia Química e Biológica (ITQB), Universidade Nova de Lisboa, Portugal (Gomes et al., 2008). 
NSC-34/hSOD1wt were used as control condition. NCS-34 cells were grown in proliferation media 
(DMEM high glucose, w/o pyruvate, supplemented with 10% of FBS and 1% of 
Penicillin/Streptomycin) and selection was made with G418 at 0.5 mg/ml. Medium was changed every 
2 to 3 days. Culture plates were coated with PDL (50 μM) before plating the cells. Cells were seeded 
in 12-well culture plates at a concentration of 5x104 cells/ml and maintained at 37ºC in a humidified 
atmosphere of 5% CO2. 
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2.1.2. N9 cell line 
N9 microglia cell line was a gift from Teresa Pais, Instituto de Medicina Molecular (IMM), Lisbon, 
Portugal. Cells were cultured in RPMI supplemented with FBS (10%), L-glutamine (1%) and 
Penicillin/Streptomycin (1%), grown to confluency and splitted every 2 to 3 days. No coating was 
required for the maintenance of these cells. In order to perform mixed cultures, cells were plated with 
NSC-34 cells in differentiation media at a concentration 2x104 cells/ml. They were maintained at 37ºC 
in a humidified atmosphere of 5% CO2. 
 
2.2. In vitro treatment of mixed cultures of NSC-34 and N9 cell lines 
After 48 h in proliferation media (as described in 2.1.1 section), differentiation of NSC-34 was 
induced by changing medium for DMEM-F12 plus FBS (1%), NEAA (1%), Penicillin/Streptomycin (1%) 
and G148 (0.1%) (Cho et al., 2011). To produce a mixed culture, we added N9 microglia cells either to 
NSC-34/hSOD1wt or NSC-34/hSOD1G93A, at time of differentiation or at two days in vitro (0 and 2 
DIV, respectively), as represented in Figure II.1. In cultures where microglia were added at 0 DIV, we 
intended to see if healthy microglia could prevent the development of MN degeneration, since neurons 
do not appear to be injured at this time. In cultures where microglia were added at 2 DIV, MN had 
already signs of degeneration, so we planned to see if microglia promote or restore MN degeneration. 
Mixed cultures were maintained in culture at 37ºC in a humidified atmosphere of 5% CO2 till 4 DIV, 
where previous studies in the group revealed high MN degeneration (Vaz et al., 2013), and till 7 DIV to 
see long term changes in microglia-MN signaling. NSC-34 cells were plated at a concentration of 
5x104 cells/ml and N9 cells at a concentration of 2x104 cells/ml, in order to maintain the usual 
proportion of microglia and neurons in the CNS, as in previous studies with mixed neuron-microglia 
cultures performed in our group (Silva et al., 2011). All of these procedures were performed in sterile 
conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II.1 Experimental procedure used in mixed cultures of transfected NSC-34 cell line and N9 cell line 
and parameters evaluated.  Neuroblastoma Spinal Cord 34 (NSC-34) cells, transfected with human superoxide 
dismutase 1 (SOD1), wild type or mutated in G93A (NSC-34/hSOD1wt or NSC-34/hSOD1G93A), were grown in 
proliferation media and selection was made with G418. After 48h in culture, differentiation was induced by 
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changing medium for Dulbecco’s modified Eagle’s medium-Ham’s F12 medium plus fetal bovine serum (1%) and 
non-essential amino acids (1%). Microglia (N9) was added at 0 and 2 DIV and cells were maintained at 4 or 7 
days after differentiation (DIV).  Accumulation of SOD1 and high-mobility group protein B1 (HMGB1) cell content 
were evaluated by western blot. Extracellular Adenosine Triphosphate (ATP) was quantified by an enzymatic 
fluorescence assay, glutamate by L-glutamic acid kit, nitric oxide (NO) by Griess reaction and matrix 
metalloproteinase-2 (MMP-2) and -9 (MMP-9) activity by gelatin zymography assay. 
 
2.3 Organotypic spinal cord culture  
 
Organotypic slice cultures were adapted from the methods previously described (Guzman-Lenis et 
al., 2009). Briefly, 7-days SJL (Wt) or transgenic mice carrying a human mSOD1 (TgSOD1-G93A 
mice), previously genotyped, were sacrificed by decapitation and their spinal cords were dissected 
using surgical equipment and a magnifying glass. After dissection, the lumbar segment of their spinal 
cord was extracted and cut into 350 μm transverse slices with a McIlwain tissue chopper. Samples 
were placed in high glucose (6 mg/ml) HBSS with 1.5% Penicillin-Streptomycin, where, they were 
separated and carefully transferred onto culture plate inserts and placed into a 6-well plate containing 
Neurobasal medium with 1x B27, 2 mM glutamine, 6 mg/ml glucose and antibiotics, and maintained at 
the air-liquid interface, at 37ºC in 5% CO2. The medium was changed the following day and, replaced 
three times per week until 10 DIV. At 10 DIV, slices were incubated with lipopolysaccharide or LPS 
(1µg/ml) for 24h, to study their influence on neuroinflammatory response in ALS. Incubations with 
Neurobasal medium were used as control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II.2 Experimental scheme of organotypic cultures of 7-days SJL (Wt) and transgenic mice carrying 
a human mSOD1 (TgSOD1-G93A mice) and parameters evaluated.  The lumbar segment of spinal cord was 
incubated in a 6-well plate and cultured during 10 days. At 10 DIV, slices were incubated with lipopolysaccharide 
or LPS (1 µg/ml) for 24h, to study their influence on neuroinflammatory response in ALS. After incubation, slices 
were collected for western blot analysis for superoxide dismutase-1 (SOD1) and Toll-like-receptor-4 (TLR-4) 
expression and extracellular media was used for quantification of nitric oxide (NO) by Griess reaction and 
Adenosine Triphosphate (ATP) by an enzymatic fluorimetric assay. 
 
2.4  Western Blot assay 
Western Blot was carried out as usual in our lab (Fernandes et al., 2006). Total cell extracts were 
obtained by lysing cells with 1x Cell Lysis Buffer plus 1 mM PMSF for 5 min, on ice and with shaking, 
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followed by sonication during 20 seconds. The lysates were centrifuged at 14000 g for 10 min, at 4ºC, 
and the supernatants were collected and stored at -20ºC.  
Homogenates from lumbar SC slices were obtained by adding ice radio-immunoprecipitation 
assay (RIPA), a lysis buffer composed by  5% of Tris(hydroxymethyl)aminomethane (Tris) 1M pH=8, 
1% of Ethylenediamine Tetraacetic acid (EDTA) 0,5M pH=8, 3% of NaCl 5M, 10% of NP-40, 50% 
glycerol, 0,1%  SDS and protease inhibitor, and homogeneized using a Pellet pestles (Sigma). Then, 
samples were treated as described for mixed cell lysates. 
Protein concentration was determined using the Bradford method (Bradford, 1976), using Bio-
Rad’s Protein Assay Reagent. Equal amounts of protein were separated on a 15% (for SOD1 and 
HMGB1 evaluation) or on a 12% (for TLR4 evaluation) sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE), running with fixed amperage of 30 mA per gel. After running the gel, 
proteins were transferred to a nitrocellulose membrane with fixed amperage of 300 mA during 1h30, 
and then blotted membranes were incubated in blocking buffer [Tween 20-Tris buffered saline (T-TBS) 
plus 0.25% (w/v) non-fat dried milk] at room temperature during 1h.  After that, membranes were 
incubated  overnight at 4ºC with the following primary antibodies diluted in T-TBS with 5% BSA: rabbit 
anti-SOD1 antibody (1:500 for cell lysates and 1:200 for tissue homogenates, Santa Cruz 
Biotechnology®), rabbit anti-TLR4 (1:100 for homogenates, Santa Cruz Biotechonlogy®), mouse anti-
HMGB1 antibody (1:500 for lysates,  BioLegend®) and mouse anti-β-actin (1:5000 for cell lysates and 
1:2000 for tissue homogenates, Sigma-Aldrich). After washing with T-TBS, the membranes were 
incubated at room temperature (RT) during 1 h with the respectively secondary antibodies: goat anti-
rabbit HRP-linked or goat anti-mouse HRP-linked (for each one 1:5000, Santa Cruz Biotechnology®), 
diluted in blocking solution. After washing membranes with T-TBS, chemiluminescent detection was 
performed by using LumiGLO® reagent, bands were visualized in Chemidoc equipment and relative 
intensities of protein bands were analyzed using the Image LabTM analysis software, both from Bio-
Rad Laboratories (Hercules, CA, USA). All the results obtained were normalized to β-actin. 
 
2.5 Quantification of extracellular ATP 
NSC-34, either alone or in mixed culture with N9 cells, as well as in organotypic culture 
extracellular media were treated on ice to avoid degradation of ATP. For the determination of 
extracellular ATP levels, the incubation media was collected and treated with perchloric acid 2M. 
Then, the pH value was neutralized with 4 M KOH solution. To remove cellular debris, the samples 
were centrifuged (Eppendorf, 5810R) during 5 min at 10,000 g and 4°C, between the different steps. 
ATP levels were measured indirectly by the production of NADPH, through an enzymatic assay 
consisting in the addition of a solution containing NADP+, glucose, 6P-glucose dehydrogenase, 
followed by hexokinase, which is the enzyme that starts the reaction. Fluorescence intensity was 
quantified using GloMax® Multi Detection System (Promega) at λem=410-460 nm and λex=365 nm.  A 
calibration curve of standard ATP was used for each assay.  
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2.6 Measurement of extracellular  glutamate  
Glutamate content was quantified in differentiation media from NSC-34, either alone or in mixed 
culture with N9 cells by using the L-glutamic acid kit (Roche). The reaction was performed in a 96-well 
microplate and the absorbance was read in the microplate reader (Bio-Rad Laboratories) at 490 nm. A 
calibration curve of glutamic acid was used for each assay. All samples and standards were analyzed 
in duplicate and the mean value was used (Falcão et al., 2005). 
 
 
2.7  Quantification of extracellular  nitric oxide/nitrite levels 
NO levels were estimated by measuring the concentration of nitrites (NO2), the stable end-product 
from NO metabolism, in the extracellular media of differentiated NSC-34 cells, either alone or in mixed 
culture with N9 cells, as well as in organotypic culture extracellular media. Cell supernatants free from 
cellular debris were mixed with Griess reagent [1% (w/v) sulphanilamide in 5% H3PO4 and 0.1% (w/v) 
N-1 naphtylethylenediamine, in a proportion of 1:1 (v/v)] in 96-well tissue culture plates for 10 min in 
the dark at room temperature. The absorbance was determined using a microplate reader (Bio-Rad 
Laboratories) at 540 nm. A calibration curve of standard nitrites was used for each assay. All samples 
were measured in duplicate and the mean value was used. 
 
2.8 Gelatin zymography 
Metalloproteinases -2 and -9 (respectively MMP-2 and MMP-9) quantification was performed in 
NSC-34, either alone or in mixed culture with N9 cells, through the gelatin zymography method, which 
is possible to detect the protease activity in the running gel. Cell supernatants free from cellular debris 
were used in SDS-PAGE zymography in 0.1 % gelatin-10 % acrylamide gels under non-reducing 
conditions, at 30 mA/gel. Then, the gels were washed for 1 h at room temperature with 2.5% Triton-X-
100 (in 50 mM Tris pH 7.4; 5 mM CaCl2; 1 μM ZnCl2) to remove SDS and to renature the MMP 
species in the gel. To induce gelatin lysis, the gels were incubated at 37°C in the developing buffer (50 
mMTris pH 7.4; 5 mM CaCl2; 1 μM ZnCl2) overnight. For enzyme activity analysis, the gels were 
stained with 0.5% Coomassie Brilliant Blue R-250 and destained in 30% ethanol/10% acetic acid/H2O. 
Gelatin activity, detected as a white band on a blue background was photographed in Chemidoc and 
measured using computerized image analysis (Image Lab) (Silva et al., 2010).  
 
2.9  Statistical analysis 
Results of at least three different experiments were expressed as mean ± SEM for NSC-34 
cultures either isolated or in mixed culture with N9. Comparisons between the different parameters 
evaluated in wt and G93A NSC-34 cell line and in organotypic cultures from SC of TgSOD1-G93A or 
WT mice were made using two-tailed Student’s t-test for equal or unequal variance, as appropriate. 
Comparison of more than two groups in the parameters evaluated in mixed cultures with or without 
microglia was done by one-way ANOVA using GraphPad Prism 5 (GraphPad Software, San Diego, 
CA, USA) followed by multiple comparisons Bonferroni post-hoc correction. p<0.05 was considered 
statistically significant and p<0.01 very significant. 
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III. RESULTS 
 
 
1. Characterization of microglia-motoneurons cross-talk in a model of 
mixed cultures of NSC-34 and N9 cell lines 
Neuroblastoma Spinal Cord 34 (NSC-34) is a hybrid cell line produced through somatic fusion 
between neuroblastoma and mice spinal cord (SC) motoneurons (MNs) from enriched primary 
cultures (Cashman et al., 1992). In our model, we used NSC-34 that had been transfected either with 
wild type (wt) human SOD1 (NSC-34/hSOD1wt) or mutated in G93A (NSC-34/hSOD1G93A) (Gomes 
et al., 2008). The characterization of these cells was recently done in our group and accumulation of 
mutated SOD1 was shown to occur after 4 days of differentiation (DIV) in NSC-34/hSOD1G93A cells, 
together with cell dysfunction (Vaz et al., 2013), which may represent the progression of MN 
degeneration in familiar ALS. Therefore, in our model, we considered two different time points after 
NSC-34 cell differentiation that could mimic two stages of MN degeneration in ALS: (i) 4 DIV – during 
SOD1 accumulation (symptomatic) and (ii) 7 DIV – after SOD1 accumulation and cell damage.  
Since ALS does not exclusively affects MN but also other cell types, and because 
neuroinflammation is a pathological hallmark of this disease, where microglia can  adquire neurotoxic 
or protective properties, we considered that it would be interesting to develop a model where cellular 
cross-talk with microglia was taken into account, since increasing evidence point microglia as key 
players for MN degeneration in ALS (Appel et al., 2011).  Therefore we studied the role of microglia in 
preventing or restoring MN function by using a model of mixed cultures, composed by N9 cell line and 
NSC-34 cell line. N9 is a microglia cell line derived from mice cortex and shares many phenotypical 
characteristics with primary cultures of mouse microglia, such as migration, phagocytosis and 
inflammation-related features (Bruce-Keller et al., 2000; Cui et al., 2002; Fleisher-Berkovich et al., 
2010).  
N9 cells were added either to NSC-34/hSOD1wt or NSC-34/hSOD1G93A, at time of neuronal 
differentiation or after two days (0 and 2 DIV, respectively), as described in Methods. In cultures where 
microglia were added at 0 DIV, we intended to see if microglia can prevent the development of the 
disease, since NSC-34/hSOD1G93A do not show to be in injured at this time point. In cultures where 
microglia were added at 2 DIV, NSC-34/hSOD1G93A already presented signs of degeneration, so we 
planned to see if microglia can rescue MN degeneration. 
 
 
1.1  Morphological characterization in NSC-34 cell line either expressing human SOD1 
wt or mutated in G93A and N9 cell line in mixed culture 
On average, the amounts of microglia and MN in vivo are near the ratio of 1/3, so NSC-34 cells 
were cultured at 2.5x104 cell/ml and N9 at 1.0x104 cell/ml as previously described (Silva et al., 2011). 
As represented in Figure III.1, we observed differentiated MNs from NSC-34 line with long extension 
of ramifications and increased number of neurites, as well as microglial cells from N9 cell line, much 
smaller and with very few or none ramifications, which are typical characteristics from this cell line 
 
42 
 
 RESULTS 
(Cashman et al., 1992; Zhao et al., 2011). We can see a higher proportion of MNs compared with 
microglia, with a ratio 3/1, confirming the proportion in vivo. 
 
Figure III. 1 - Mixed cultures of NSC-34 cell line and microglial cells from N9 cell line, were 
successfully implemented and represent the ratio 3/1 as previously described (Silva et al., 2011). Cells 
were cultured as indicated in Methods. (A) After fixation with paraformaldehyde, cells collected at 4 DIV were 
double-stained with mouse anti-βIII-tubulin for neurons and with rabbit anti-lectin for microglia followed by a 
fluorescent-labeled secondary antibody (neurons in red and microglia in green), and counterstained with 
Hoechst® for the nuclei (in blue). (B) Photos of mixed culture in phase-contrast microscope were acquired 
after MNs differentiation and taken by a digital HP camera. Scale bar represents 40 μm. 
 
1.2 Microglia restore human SOD1 (hSOD1) accumulation as well as mouse SOD1 
accumulation in NSC-34/hSOD1G93A after 7 DIV 
The analysis of SOD1 accumulation was performed by western blot analysis of mixed culture cell 
lysates. As indicated in Figure III.2, we detected two bands with low molecular weight in NSC-
34/hSOD1wt and NSC-34/hSOD1G93A cells, which correspond to human and mouse forms of SOD1, 
with 21 and 14 kDa respectively (Kirby et al., 2005), confirming the success of the transfection of 
hSOD1.  
                       
 
 
 
 
Figure III. 2 NSC-34 cells contain human SOD1 (hSOD1) successfully transfected and 
mouse SOD1. Cells were cultured as indicated in Methods. Total lysates were analyzed by 
western blot with anti-SOD1 antibody. Anti-β-actin antibody was used as internal control. 
Representative results from one experiment are shown. 
 
To study the effects of microglia in SOD1 accumulation in NSC-34/hSOD1G93A cells, we 
performed western blot assay using rabbit anti-SOD1 antibody (1:500). Regarding human SOD1 
B A 
 
43 
 
 RESULTS 
(hSOD1), and as indicated in Table III.1 and Figure III.3B, the results showed a significant increase of 
protein accumulation in NSC-34/hSOD1G93A cells, when compared with respective control after 7 
DIV (p<0.01 vs. respective NSC-34/hSOD1wt) and respective 4 DIV condition (p<0.01). Here, the 
presence of microglia reduced very significantly hSOD1 accumulation in NSC-34/hSOD1G93A, 
especially when it was added at 2 DIV (p<0.01). No significant alterations were seen after 4 DIV.  
Regarding mouse SOD1, there was a significant increase in its content in NSC-34/hSOD1G93A after 
4 DIV and 7 DIV, when compared with the respective control (Table III.1 and figure III.3.C). The 
addition of microglia at 0 and 2 DIV reduced very significantly mouse SOD1 accumulation in NSC-
34/hSOD1G93A after 7 DIV (p<0.01 vs. NSC-34/hSOD1G93A w/o microglia addition and p<0.01 vs. 
respective 4 DIV condition). 
 
Table III.1 – Levels of human and mouse superoxide dismutase 1 (SOD1) are augmented in NSC-
34/hSOD1G93A cells and reduced in the presence of microglia after 7 DIV. 
 
Cells were cultured as indicated in Methods. Total cell lysates were collected at 4 DIV and 7 DIV and both 
analyzed by western blot with antibody specific for SOD1. The intensity of the bands was quantified using image 
analysis software (Image Lab), normalized with respect to β-actin protein. Data are expressed as fold vs. NSC-
34/hSOD1wt and represent the absolute values found in Figure III.3. Results are mean ± SEM from at least two 
independent experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 w/o N9 + N9 at 0 DIV + N9 at 2 DIV 
Human 
SOD1 
4 DIV 
NSC-34/hSOD1wt 1.00 ± 0.43 1.20 ± 0.17 0.61 ± 0.08 
NSC-34/hSOD1G93A 0.93 ± 0.08 1.75 ± 0.22 1.48 ± 0.39 
7 DIV 
NSC-34/hSOD1wt 1.00 ± 0.90 0.92 ± 0.16 0.96 ± 0.37 
NSC-34/hSOD1G93A 2.35 ± 0.78 1.73 ± 0.43 0.38 ± 0.17 
Mouse 
SOD1 
4 DIV 
NSC-34/hSOD1wt 1.00 ± 0.54 1.03 ± 0.14 1.06 ± 0.10 
NSC-34/hSOD1G93A 1.04 ± 0.34 1.47 ± 0.22 1.02 ± 0.25 
7 DIV 
NSC-34/hSOD1wt 1.00 ± 0.86 1.26 ± 0.24 0.88 ± 0.12 
NSC-34/hSOD1G93A 1.30 ± 0.47 0.54 ± 0.03 0.58 ± 0.10 
 
44 
 
 RESULTS 
A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III. 3 - Human and mouse superoxide dismutase 1 (SOD1) levels are increased in NSC-
34/hSOD1G93A cells and reduced in the presence of microglia after 7 DIV. Cells were cultured as indicated 
in Methods. Total cell lysates were collected at 4 DIV and 7 DIV and both analyzed by western blot with antibody 
specific for SOD1. (A) Representative results from one experiment are shown. The intensity of the bands was 
quantified using image analysis software (Image Lab), normalized with respect to β-actin protein and expressed 
as fold vs. respective NSC-34/hSOD1wt condition, either for human SOD1 (B) or for mouse SOD1 (C). Results 
are mean ± SEM from at least two independent experiments. Corresponding absolute values are presented in 
Table III.1. **p<0.01 and *p<0.05 vs. respective NSC-34/hSOD1wt condition; ##p<0.01 vs. respective NSC-
34/hSOD1G93A w/o microglia; $$p<0.01 and $p<0.05 vs. respective 4 DIV condition. Dotted line: respective wt 
(control). 
 
 
1.3 Microglia differently modulate nitric oxide (NO), glutamate and Adenosine 
Triphosphate (ATP) extracellular levels in mixed culture with NSC-34/hSOD1G93A 
It is known that abnormal accumulation of SOD1-positive inclusions in spinal MNs is a 
pathological hallmark in SOD1-related familial ALS (Furukawa, 2012). Moreover, these aggregates 
accumulate in vacuoles in the mitochondrial intermembrane space, leading to their dysfunction. 
Consequently, Adenosine Triphosphate (ATP) production and calcium buffering are deregulated and 
can increase the susceptibility of MNs to the altered calcium homeostasis associated with glutamate-
mediated excitotoxicity (Ferraiuolo et al., 2011). Thus, we next investigated their release by MNs from 
NSC-34 cell line in the presence or absence of healthy microglia.  
Glutamate plays an important role in ALS, since it is responsible for the excitotoxicity event. In 
our results, we observed a reduction in glutamate release of NSC-34/hSOD1G93A after 4 DIV (p<0.05 
vs. respective NSC-34/hSOD1wt) and 7 DIV, as we can see in table III.2 and figure III.4.A. After 4 DIV, 
the presence of microglia added at 0 DIV (prior to MN dysfunction) increased glutamate levels 
(although not statistically significant) but did not exert any effect when added at 2 DIV (Figure.III.4.A). 
However, microglia added at 2 DIV significantly increased the levels of glutamate release by mixed 
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microglia-NSC-34/hSOD1G93A cultures after 7 DIV (p<0.01 vs. respective NSC-34/hSOD1G93A and 
p<0.01 vs. respective 4 DIV condition).  
Another player in ALS-mediated neurotoxicity is nitric oxide (NO), which contributes for 
oxidative stress and neuroinflammation. Indeed, in our model, we observed an increase of NO levels 
in NSC-34/hSOD1G93A cells (Table III.2 and FigureIII.4.B) either after 4 or 7 DIV (p<0.05 vs. 
respective NSC-34/hSOD1wt after 4 or 7 DIV). The presence of microglia added at 0 DIV significantly 
increased NO release after 4 DIV, however the opposite effect was observed in mixed cultures after 7 
DIV (p<0.05 vs. respective NSC-34/hSOD1G93A w/o microglia).  
An increase in extracellular ATP content, resulting damaged neurons was also considered an 
important marker for neurodegeneration (Glass et al., 2010). These higher extracellular ATP levels will 
in turn activate microglia through purinergic receptors (D'Ambrosi et al., 2009). Interestingly, here we 
observed an increase of extracellular ATP levels in NSC-34/hSOD1G93A cells (Table III.2 and 
FigureIII.4.C) after 4 DIV but mostly after 7 DIV (p<0.01 vs. respective NSC-34/hSOD1wt). The 
presence of microglia added at 2 DIV significantly reduced ATP release in mixed microglia-NSC-
34/hSOD1G93A cultures after 7 DIV (p<0.01 vs. respective NSC-34/hSOD1G93A w/o microglia).  
 
 
 
 
Cells were cultured as indicated in Methods. After differentiation, extracellular media collected at 4 DIV and 7 DIV was 
assessed for glutamate release by L -glutamic acid kit and the absorbance was measured in a microplate reader; NO 
production by Griess reaction and absorbance was measured in the microplate reader; ATP release by an enzymatic 
assay and fluorescence intensity was quantified using a fluorimetric assay. Results are expressed in μM and represent 
the absolute values found in Figure III.4. Results are mean ± SEM in at least four independent experiments performed in 
duplicate. **p<0.01 and *p<0.05 vs. respective NSC-34/hSOD1wt condition; #p<0.05 vs. respective NSC-
34/hSOD1G93A w/o microglia; $$p<0.01 and $p<0.05 vs. respective 4 DIV condition. 
 w/o N9 + N9 at 0 DIV + N9 at 2 DIV 
Glutamate 
4 DIV 
NSC-34/hSOD1wt 474 ± 89 442 ± 86 399 ± 148 
NSC-34/hSOD1G93A 310 ± 55 285 ± 74 324 ± 61 
7 DIV 
NSC-34/hSOD1wt 539 ± 85 373 ± 74 251 ± 89 
NSC-34/hSOD1G93A 409 ± 51 326 ± 71 229 ± 12 
NO 
4 DIV 
NSC-34/hSOD1wt 1.18 ± 0.11 1.09 ± 0.19 1.08 ± 0.13 
NSC-34/hSOD1G93A 1.82 ± 0.20* 1.95 ± 0.21 2.21 ± 0.25 
7 DIV 
NSC-34/hSOD1wt 0.88 ± 0.05 1.10 ± 0.09 1.74 ± 0.34 
NSC-34/hSOD1G93A 2.50 ± 0.31** 1.98 ± 0.33 3.94 ± 0.12 $$ 
ATP 
4 DIV 
NSC-34/hSOD1wt 25.51 ± 0.95 24.92 ± 1.07 25.49 ± 1.26 
NSC-34/hSOD1G93A 28.26 ± 1.52 26.25 ± 1.12 27.45 ± 2.09 
7 DIV 
NSC-34/hSOD1wt 28.59 ± 0.80 28.24 ± 1.54 28.47 ± 1.38 
NSC-34/hSOD1G93A 37.15 ± 3.38*$ 32.33 ± 2.83 28.90 ± 1.61# 
Table III.2 – Metabolic function  are altered in differentiated NSC-34/hSOD1G93A cells, evidenced by 
increased production/release of glutamate, Nitric Oxide (NO) and Adenosine Triphosphate (ATP), which 
are modulated by the presence of microglia in mixed cultures. 
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Figure III. 4 – Differentiated NSC-34/hSOD1G93A cells have altered metabolic function, evidenced by 
increased production/release of glutamate, Nitric Oxide (NO) and Adenosine Triphosphate (ATP), which 
are modulated by the presence of microglia in mixed cultures. Cells were cultured as indicated in Methods. 
After differentiation, extracellular media collected at 4 DIV and 7 DIV was assessed for (A) glutamate release by 
L-glutamic acid kit and the absorbance was measured in a microplate reader; (B) NO production by Griess 
reaction and absorbance was measured in the microplate reader; (C) ATP release by an enzymatic assay and 
fluorescence intensity was quantified using a fluorimetric assay. All the results are mean (± SEM) and expressed 
as fold vs. respective NSC-34/hSOD1wt condition from at least four independent experiments performed in 
duplicate. Corresponding absolute values are presented in Table III.2. **p<0.01 and *p<0.05 vs. respective NSC-
34/hSOD1wt condition; ##p<0.01 and #p<0.05 vs. respective NSC-34/hSOD1G93A w/o microglia; $$p<0.01 vs. 
respective 4 DIV condition. Dotted line: respective wt (control). 
 
 
1.4  Microglia prevent and restore efflux of neuroinflammatory associated markers in 
NSC-34/hSOD1 G93A cells  
Neuroinflammation is a pathological hallmark of ALS and include the activation and proliferation of 
microglia. Although often considered a consequence of neuronal injury and degeneration, the 
neuroinflammatory response can have protective or deleterious effects on neuronal survival (Lewis et 
al., 2012). Matrix metalloproteinases (MMPs) are important players in neuroinflammation and recent 
studies have associated their actions to neurodegenerative disorders. They regulate extracellular 
matrix structure and can affect cell signaling initiated by growth factors or death receptors (Rosenberg, 
2009). In our model of mixed cultures, we were able to detect bands with 72 kDa and 92 kDa (Figure 
III.5A), corresponding to MMP-2 and MMP-9, respectively (Yong et al., 2001). We observed an 
increase in MMP-2 in NSC-34/hSOD1G93A after 7 DIV (Figure III.5B) and in MMP-9 (Figure III.5C) 
after 4DIV (p<0.05 vs. respective NSC-34/hSOD1wt) and 7 DIV. Furthermore, we saw differences in 
activation of MMPs when microglia is present. Indeed, microglia added at 2 DIV reduced MMP-2 
levels in mixed cultures of microglia with NSC-34/hSOD1G93A after 4 DIV (Table III.3 and Figure 
III.5.B). These reduction was very significant and significant after 7 DIV for microglia added either at 0 
A 
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or 2 DIV, respectively (p<0.01 and p<0.05 vs. respective NSC-34/hSOD1wt). In respect to MMP-9, 
after 4 DIV, the addition of microglia significantly reduced MMP-9 levels (p<0.01 vs. respective NSC-
34/hSOD1wt), while after 7 DIV, only microglia added at 2 DIV was able to reduce them. 
 
 
 
Cells were cultured as indicated in Methods. After differentiation, extracellular media collected at 4 DIV and 7 DIV 
was assessed for MMPs activity by gelatin zymography assay. The intensity of the bands was quantified using 
computerized image analysis (Image Lab) for MMP-2 and -9. Results are expressed as fold vs. NSC-34/hSOD1wt 
and represent the absolute values found in Figure III.5. Results are mean ± SEM from at least two independent 
experiments, performed in duplicate. $p<0.01 vs. respective 4 DIV condition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 w/o N9 + N9 at 0 DIV + N9 at 2 DIV 
MMP-2 
4 DIV 
NSC-34/hSOD1wt 1.00 ± 0.13 0.74 ± 0.16 1.36 ± 0.24 
NSC-34/hSOD1G93A 0.95 ± 0.17 0.84 ± 0.15 0.46 ± 0.05 
7 DIV 
NSC-34/hSOD1wt 1.00 ± 0.19 0.61 ± 0.19 0.50 ± 0.11$ 
NSC-34/hSOD1G93A 0.98 ± 0.25 0.50 ± 0.12 0.37 ± 0.06 
MMP-9 
4 DIV 
NSC-34/hSOD1wt 1.04 ± 0.06 0.98 ± 0.09 0.99 ± 0.10 
NSC-34/hSOD1G93A 0.90 ± 0.17 0.77 ± 0.11 0.45 ± 0.19 
7 DIV 
NSC-34/hSOD1wt 0.93 ± 0.09 1.76 ± 0.22$ 1.33 ± 0.13 
NSC-34/hSOD1G93A 1.23 ± 0.23 1.48 ± 0.23$ 0.68 ± 0.19 
A 
Table III.3 – Activation of matrix metalloproteinases-2 and -9 (MMP-2 and MMP-9) is elevated in 
NSC-34/hSOD1G93A cells after differentiation, which are modulated by the presence of 
microglia in mixed cultures. 
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Figure III. 5 Matrix metalloproteinases-2 and -9 (MMP-2 and MMP-9) activation is elevated in NSC-
34/hSOD1G93A cells after differentiation, which are modulated by the presence of microglia in mixed 
cultures. Cells were cultured as indicated in Methods. After differentiation, extracellular media collected at 4 DIV 
and 7 DIV was assessed for MMPs activity by gelatin zymography assay. Representative results from one 
experiment are shown (A). Similar results were obtained in at least two independent experiments. The intensity of 
the bands was quantified using computerized image analysis (Image Lab) for MMP-2 (B) or MMP-9 (C), and 
expressed as mean ± SEM fold change compared with respective NSC-34/hSOD1wt condition. Corresponding 
absolute values are presented in Table III.3. *p<0.05 vs. respective NSC-34/hSOD1wt condition; ##p<0.01 and 
#p<0.05 vs. respective NSC-34/hSOD1G93A w/o microglia. Dotted line: respective wt (control). 
 
 
1.5 Microglia increase High Mobility Group Box 1 (HMGB1) levels in NSC-
34/hSOD1G93A cells after 4 DIV and reduce them after 7 DIV 
Finally, a particular attention was given to High Mobility Group Box 1 (HMGB1), a ubiquitous 
nuclear protein released by necrotic cells or stimulated monocytes, which participate in activation of 
innate immune response, including chemotaxis and cytokine release (Yang et al., 2013). In fact, 
evidence suggests a contribution of HMGB1 in many inflammatory diseases (Kim et al., 2006), which 
may be a key point to consider in ALS pathophysiology. To study the effects of microglia in production 
of HMGB1 by NSC-34 cells, we performed western blot assay using mouse anti-HMGB1 antibody 
(1:500). After 4 DIV and 7 DIV, we observed a marked increase of HMGB1 levels (although not yet 
statistically significant) in NSC-34/hSOD1G93A, compared to respective control condition (Table III.4 
and Figure III.6.B). Moreover, the addition of microglia at 0 DIV slightly increased HMGB1 levels after 
4 DIV. Interestingly, after 7 DIV, there was a reduction of HMGB1 levels when microglia was added at 
0 and 2 DIV, suggesting that this protein was released to the extracellular media.  
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Cells were cultured as indicated in Methods. Total cell lysates were collected after 4 DIV and 7 DIV and both 
analyzed by western blot with antibody specific for HMGB1. Results were obtained in at least two independent 
experiments. The intensity of the bands was quantified by using computerized image analysis (Image Lab) and 
standardized with respect to β-actin protein. Results are expressed as fold vs. NSC-34/hSOD1wt and represent 
the absolute values found in Figure III.6.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Together, these results suggest that microglia differently modulate signaling mechanisms that are 
involved in MN degeneration along ALS progression, which depends on the time in culture and also on 
the level of degeneration they face when in culture with NSC-34/hSOD1G93A. 
 
 w/o N9 + N9 at 0 DIV + N9 at 2 DIV 
HMGB1 
4 DIV 
NSC-34/hSOD1wt 1.00 ± 0.72 0.56 ± 0.10 0.56 ± 0.16 
NSC-34/hSOD1G93A 1.24 ± 0.30 1.05 ± 0.09 1.10 ± 0.24 
7 DIV 
NSC-34/hSOD1wt 1.00 ± 0.80 1.07 ± 0.33 0.68 ± 0.18 
NSC-34/hSOD1G93A 1.89 ± 0.60 3.14 ± 0.54 0.54 ± 0.12 
B 
A 
Figure III. 6 – High-mobility-group-box-protein-1 
(HMGB1) is elevated in NSC-34/hSOD1G93A cells 
after differentiation, which is differently 
modulated by the presence of microglia in mixed 
cultures. Cells were cultured as indicated in 
Methods. Total cell lysates were collected after 4 DIV 
and 7 DIV and both analyzed by western blot with 
antibody specific for HMGB1. Representative results 
from one experiment are shown (A). Similar results 
were obtained in at least two independent 
experiments. The intensity of the bands was 
quantified (B) by using computerized image analysis 
(Image Lab), standardized with respect to β-actin 
protein and expressed as mean ± SEM fold change 
compared with respective NSC-34/hSOD1wt 
condition (B). Corresponding absolute values are 
presented in Table III.4. Dotted line: respective wt 
(control). 
 
 
Table III. 4 – Elevation of High-mobility-group-box-protein-1 (HMGB1) is observed in NSC-
34/hSOD1G93A cells after differentiation, which is differently modulated by the presence of 
microglia in mixed cultures. 
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2.  Establishing organotypic slice culture as a model for study ALS 
Organotypic cultures are a model that is biochemically and physiologically more similar to the 
in vivo tissue since it preserves interneuronal connections and key processes. Moreover, it is a 
powerful model to screen the efficacy of potential therapies (Su et al., 2011). In order to 
approximate the in vivo conditions that lead to ALS development, we developed an organotypic 
culture composed by slices of lumbar SC from transgenic mice carrying a human mutant-SOD1 
(TgSOD1-G93A). Organotypic cultures from SC of 7-days SJL WT mice were used as controls. 
 
2.1 Implementation and characterization of SC organotypic cultures 
Here, we focused our attention on lumbar segments from SC, since it is considered one of the 
most affected neural tissues in ALS (Chen et al., 2010). We were able to implemment the proposed 
model and after 11 days in culture we observed an intact and functional structure of the lumbar tissue 
where it was possible to identify posterior and anterior horn and central canal, as as schematically 
represented in Figure III.7 after histological analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III. 7- Schematic representation of a transversal section of the lumbar spinal cord. Original 
magnification 100x. 
 
After the implementation of the organotypic culture model, we analyzed the parameters found 
to be altered on the section 1 from Results. At this moment, we have focused on SOD1 accumulation, 
NO and extracellular ATP levels. In addition, we also quantified the extracellular levels of NO and ATP 
upon an inflammatory response triggered by incubation with lipopolysaccharide (LPS). The expression 
of toll-like receptor 4 (TLR4), a receptor responsible for LPS recognition and the triggering of 
production of neurotoxic pro-inflammatory mediators and NO, was also quantified. 
 
2.2 Mouse and hSOD1 accumulation is highly increased in transgenic mouse 
The analysis of SOD1 accumulation was performed by western blot analysis of homogenates, 
using rabbit anti-SOD1 antibody (1:200). Preliminary results pointed a great increase, although not yet 
significant, of SOD1 accumulation in TgSOD1-G93A mice (Figure III.8). 
 
51 
 
 RESULTS 
A
0
30
60
90
120
150
S
O
D
1
 
(f
o
ld
 v
s
. 
S
J
L
 w
t)
WT                        TgSOD1-G93A
B
0
25
50
75
100
125
150
175
E
x
tr
a
c
e
llu
la
r 
A
T
P
 (
μ
M
)
WT                                    TgSOD1-G93A
B
0.0
0.5
1.0
1.5
N
O
(μ
M
)
WT                                     TgSOD1-G93A
CA B
 
 
 
 
 
 
 
 
 
Figure III. 8 – Superoxide dismutase 1 (SOD1) levels are increased in TgSOD1-G93A mice. Lumbar spinal 
cord slices were cultured as indicated in Methods. Total homogenate was analyzed by western blot with specific 
antibody for SOD1. Representative results from one experiment are shown (A). The intensity of the bands was 
quantified (B) using computerized image analysis (Image Lab), standardized with respect to β-actin protein and 
expressed as mean ± SEM from three independent experiments. 
 
 
2.3 LPS does not have a significant effect on NO release but is able to reduce 
extracellular ATP in TgSOD1-G93A mice  
LPS exists in the outer membrane of Gram-negative bacteria and act as an endotoxin that elicit 
strong immune responses in animals. As depicted in Figure III.9.A no differences in NO levels 
were observed between wt and TgSOD1-G93A mice, either in the presence or absence of LPS. 
Interestingly, preliminary results suggested that TgSOD1-G93A mice have a slight reduction of 
extracellular ATP, which is enhanced after LPS exposure (Figure III.9B).  
 
 
 
 
 
 
 
Figure III. 9 - Lipopolysaccharide (LPS) does not have any significant effect in Nitric Oxide (NO) levels but 
reduce extracellular levels of Adenosine Triphosphate (ATP) in TgSOD1-G93A mice. Lumbar spinal cord 
slices were cultured for 10 days and incubated with 1µg/ml LPS for 24 h, as indicated in Methods. After 
incubation, extracellular media was assessed for (A) NO production/release by Griess reaction and absorbance 
was measured in the microplate reader or (B) ATP release by an enzymatic assay and fluorescence intensity was 
quantified using a fluorimeter.  Results are mean ± SEM from at least two independent experiments.  
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2.4 LPS reduce levels of TLR4 receptor in wt and TgSOD1-G93A mice 
The analysis of levels of TLR4 was performed by western blot analysis of homogenates, using 
rabbit anti-TLR4 antibody (1:100). As indicated in figure III.10.A, we were able to detect one band with 
95 kDa  in either wt or TgSOD1-G93A homogenate samples, confirming the presence of this receptor 
(Yao et al., 2013). As shown in figure III.10.B, incubation with LPS seemed to reduce the levels of this 
receptor in namely in the TgSOD1-G93A,mice, suggesting loss of microglia response in terms of its 
activation mediated through these receptor (Yao et al. 2013). However, these are still preliminary 
results, which require further confirmation. 
 
 
 
 .  
Figure III. 10 – Incubation with lipopolysaccharide (LPS) is suggested to reduce the levels of Toll-like 
receptor 4 (TLR4), especially in cultures from TgSOD1-G93A mice.  Lumbar spinal cord slices were cultured 
for 10 days and incubated with 1µg/ml LPS for 24 h, as indicated in Methods. After incubation, total homogenate 
was analyzed by western blot with antibody specific for TLR4. Representative results from one experiment are 
shown (A). The intensity of the bands was quantified (B) using computerized image analysis (Image Lab), 
standardized with respect to β-actin protein and expressed as mean ± SEM from at least two independent 
experiments. Dotted line: respective wt (control). 
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IV. DISCUSSION 
 
 
ALS is epidemiologically classified into two forms: sporadic (90%-95%) and familial (5%-10%). 
Among the familial cases, approximately 20% are caused by dominantly inherited mutations in the 
Cu/Zn superoxide dismutase-1 (SOD1) protein (Musaro, 2010). Consequently, many experimental in 
vitro and in vivo models including mutations in this enzyme have been developed to improve our 
understanding of the disease and have allowed the testing of possible therapeutic strategies. In our 
studies, we have used mixed cultures of Neuroblastoma Spinal Cord 34 (NSC-34) cell line with N9 cell 
line. NSC-34 cells present characteristics of motoneuron (MN), such as acetylcholine synthesis, 
storage and release, generation of potential generation, expression of neurofilament proteins and 
association with neuromuscular synapse-specific basal lamina glycoproteins (Tovar et al., 2009). They 
respond to stimuli affecting voltage-gated ion channels, organization of cytoskeleton and axonal 
transport, very similar with primary MN, although they cannot reproduce synaptic connections when 
are at an undifferentiated stage (Durham et al., 1993). In our work, we have used this cell line 
transfected with human SOD1G93A (NSC-34/hSOD1G93A) protein, where there is a change in the 
aminoacid 93 from one glycine to one alanine. These cells are described to produce many features of 
MN degeneration in ALS, like Golgi apparatus fragmentation (Gomes et al., 2008) and mitochondrial 
deregulation (Raimondi et al., 2006). Recently, in our group it was demonstrated that NSC-
34/hSOD1G93A cells present accumulation of SOD1 after 4 days of differentiation (DIV), together with 
cell dysfunction (Vaz et al., 2013), which may represent the progression of MN degeneration in familiar 
ALS. Thus, here we considered two different time points after NSC-34 cell differentiation: (i) 4 DIV – 
during SOD1 accumulation (symptomatic) and (ii) 7 DIV – after SOD1 accumulation and MN cell 
death.  
The increased number of non-neuronal cells from CNS considered to be affected in the rodent 
model as well as in ALS autopsies has long been considered to be a secondary response to MN 
degeneration (Dewil et al., 2007).  In addition, some studies pointed that activated microglia, 
considered the primary immune cells of the CNS, may contribute to MN protection or instead to MN 
injury and consequent cell death (Boillee et al., 2006). In our model of mixed cultures we intended to 
see if healthy microglia was able to prevent, promote or restore MN neurodegeneration, and also to 
explore long term changes in microglia-MNs cross-talk. First, we implemented and characterized the 
mixed culture in our lab with these two types of cells, and we confirmed that N9 cells were able to 
maintain their capacities when moved from their proliferative medium to NSC-34 differentiation 
medium. In fact, Guo and colleagues (2013) have maintained N9 cells in a similar medium, also with 
the basis of Dulbecco's Modified Eagle Medium/F12. Differentiation of NSC-34 cells also transformed 
these cells into a MN-like-morphology, has been previously described (Cho et al., 2011; Matusica et 
al., 2008). They appeared with long ramifications and increased number of neurites until 4 and 7 DIV. 
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Stable transfection of SOD1 was confirmed by Western Blot analysis, with two bands 
corresponding to human and mouse forms of SOD1, with 21 and 14 kDa, respectively (Kirby et al., 
2005). Many SOD1 aggregates were found in fALS cases, cell culture models (Ferraiuolo et al., 2011) 
as well as in brain and in spinal cord (SC) of the transgenic (TgSOD1-G93A) mice (Redler and 
Dokholyan, 2012). In our results, human SOD1 (hSOD1) accumulation was significantly increased in 
NSC-34/hSOD1G93A after 7 DIV, when compared with respective controls (NSC-34/hSOD1wt). This 
increase was much more evident than the one also found for mouse SOD1 accumulation, which can 
be explained by the greater susceptibility of oxidation-induced aggregation of fALS-associated SOD1 
mutations harbored by transgenic mice (Rakhit et al., 2002). It was also observed that microglia 
reduced SOD1 accumulation in NSC-34/hSOD1G93A cells, possibly because microglia is able to 
phagocyte SOD1 aggregates. In fact, microglia has the capacity to phagocyte cellular debris, including 
protein aggregates, as it was demonstrated by Chung and colleagues (1999), where microglia from 
mixed glial cultures could uptake, degrade, and release smaller aggregates of fibrillar or even soluble 
amyloide-beta peptide, present in Alzheimer’s disease. Moreover, in studies with chimeric mice, it was 
demonstrated that non-neuronal cells that do not express mutant SOD1 can ameliorate MN 
degeneration and death of mutant SOD1 cells. (Clement et al., 2003). Curiously, in our model, the 
reduction of SOD1 levels was even more evident when MNs and microglia were in contact for longer 
time. Since SOD1 accumulation in mutated MNs increases along ALS progression (Jaarsma et al., 
2008), we may speculate that healthy microglia, in some way, is trying to reduce such accumulation. It 
would be interesting to determine which signaling mechanisms may be mediated by SOD1 
aggregates, such as phagocytic microglia ability but also signaling pathways involved in 
neuroinflammation.  
SOD1 aggregates accumulate in vacuoles in the mitochondrial intermembrane space, leading 
to their dysfunction. Consequently, Adenosine Triphosphate (ATP) production and calcium buffering 
may become deregulated, which may increase the susceptibility of MNs to the altered calcium 
homeostasis associated with glutamate-mediated excitotoxicity in ALS (Pasinelli and Brown, 2006). In 
our model, we observed a reduction in glutamate release by differentiated NSC-34/hSOD1G93A cells 
in comparison with NSC-34/hSOD1wt, contradicting previous studies where high levels of glutamate in 
cerebrospinal fluid (CSF) of some patients with ALS were observed (Rothstein et al., 1995). In 
addition, hyperexcitability of the motor system at early stages of ALS is described, through 
electrophysiological studies in humans (Vucic and Kiernan, 2006). Our result may be explained by the 
mitochondrial dysfunction that may have resulted from the reduction of the glucose-derived pyruvate 
flow through the  tricarboxylic acid cycle and decreased glutathione content, which will alter glutamate 
metabolism (D'Alessandro et al., 2011). In addition, the presence of microglia added at 2 DIV 
significantly increased the levels of glutamate released in mixed microglia-neuronal cultures, 
especially when cells are in contact for longer time (7 DIV), suggesting that microglia is activated upon 
contact with NSC-34/hSOD1G93A. In fact, excitotoxicity by glutamate released from activation of 
microglia is considered a major cause of axonal degeneration (Yawata et al., 2008).  
Regarding ATP, we observed higher extracellular ATP levels in NSC-34/hSOD1G93A, which 
may also promote activation microglia through purinergic receptors (D'Ambrosi et al., 2009), probably 
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as an attempt to resolve the extension of the lesion. However, this is a small increase, probably 
derived from metabolic failure at the level of mitochondria in NSC-34/hSOD1G93A (D'Alessandro et 
al., 2011). Moreover, our results show that interaction between microglia and NSC-34/hSOD1G93A for 
longer time (7 DIV) also led to a reduction of extracellular ATP levels. Indeed, ATP acts as a neuron-
to-microglia alarm signal, through cell surface P2 receptors widely distributed throughout the CNS. In 
ALS patients (Yiangou et al., 2006), as well as SOD1 G93A animals (Casanovas et al., 2008), an 
increased immunoreactivity for P2X was found in SC microglia. This probably occurs because ATP 
binds to P2X receptors present in microglia, reducing their presence in extracellular media. 
Neuroinflammation is a pathological hallmark of ALS, which includes the activation and 
proliferation of microglia. To see the influence of healthy microglia in inflammatory response, we 
investigated the release of nitrites/nitric oxide (NO) and metalloproteinases-9 and -2 (MMP-9 and -2) 
by MNs. We observed increased NO levels released by NSC-34/hSOD1G93A (p<0.05 vs. NSC-
34/hSOD1wt). Conversely, studies of CSF and human postmortem CNS tissue from ALS patients 
showed biochemical changes that represent the effect of free radical damage or abnormal free radical 
metabolism (Ferrante et al., 1997; Shaw et al., 1995; Smith et al., 1998; Tohgi et al., 1999). In 
addition, mutated SOD1 has an imperfect folding, which disables their normal function as an 
antioxidant, instead it will favor an increase of superoxide anion production, which reacts with NO to 
produce peroxynitrite, ultimately causing tyrosine nitration (Barber and Shaw, 2010). In fact, a product 
of tyrosine nitration is 3-nitrotyrosine, which was widely detected in the MNs of sporadic cases with 
ALS (Abe et al., 1997). When microglia were present with NSC-34/hSOD1G93A during 2 and 4 DIV, 
extracellular NO levels increased. Again, this suggests a microglia activation pattern, with consequent 
production and release of NO through an up-regulation of inducible nitric oxide synthase, such as the 
one found in microglia cocultured neurons after exposure to lipopolysaccharide (LPS) (Zhao et al., 
2004). When NSC-34/hSOD1G93A and microglia are maintained together until 7 DIV, it occurs a 
significant reduction of NO levels (p<0.05), suggesting a switch of microglia activation pattern. 
In respect of metalloproteinases (MMPs), activity of MMP-2 increased in NSC-34/hSOD1G93A 
after 7 DIV and in MMP-9 after 4DIV (p<0.05 vs. respective NSC-34/hSOD1wt) and 7 DIV, confirming 
results performed by Fang and colleagues (2010), where MMP-2 and -9 activation was increased in 
SC of transgenic SOD1G93A mice. Soon and colleagues (2010) also showed that MMP-2 and -9 
activity was significantly elevated in serum of SOD1G93A mice at the early symptomatic stage of ALS, 
decreasing thereafter during disease progression till end stages. In our model, when microglia were 
placed in contact with NSC-34/hSOD1G93A cells, a reduction of MMP-2 and -9 activity occurred. 
Thus, we proposed the intervention of inhibitors of matrix metalloproteinases (TIMPs), family of four 
related proteins capable of binding and inhibit MMPs activity, through tight non-covalent complexes. In 
CSF samples from ALS-patients, high levels of TIMP-1 and no MMP-9 activity were detected (Lorenzl 
et al., 2003). A recent study, also performed in CSF samples from ALS-patients, showed an increase 
of TIMP-1 level and a decrease of MMP-9 activity (Niebroj-Dobosz et al., 2007). TIMPs play a critical 
role in maintaining tissue proteolysis homeostasis and microglia play a fundamental role in mediating 
tissue breakdown and repair. Therefore, Welser-Alves and colleagues (2011) found that microglia play 
a central role in regulating glial cell expression of TIMPs, using primary mixed glial cultures, composed 
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by microglia and astrocytes obtained from 0-2 day old C57Bl/6 mouse pups. So, we may suggest that 
in our model, microglia is producing TIMP-1, in order to inhibit MMPs activation in NSC-
34/hSOD1G93A.  
High Mobility Group Box 1 (HMGB1) is a non-histone structural protein located within the 
nucleus. Passive release of HMGB1 from the nucleus represents a signal of cell injury, which triggers 
the release of pro-inflammatory factors and thus activates cellular processes that stimulate tissue 
regeneration (Hwang et al., 2013). It is involved in many inflammatory diseases, which may be a key 
point to consider in ALS pathophysiology. Although no different expression pattern was observed by 
Lo Coco and colleagues (2007) in SC tissue of SOD1-G93A transgenic mice at presymptomatic stage 
as compared with controls, the levels of HMGB1 and other proteins involved in HMGB1 function, such 
as toll-like receptors-2 and -4 (TLR-2 and TLR-4, respectively), as well as serine/threonine kinase 30 
were elevated in SC tissues of patients with ALS (Casula et al., 2011). We found an increase in 
HMGB1 content in NSC-34/hSOD1G93A, either for 4 or 7 DIV, for the first time in a model of mixed 
cell line culture applied for the study of ALS. Moreover, we demonstrated that the addition of microglia 
at 0 DIV enhanced intracellular HMGB1 levels in culture until 4 DIV. In fact it is described an intensely 
widely distributed HMGB1 content in the nucleus of reactive glial cells from SC tissue of SOD1-G93A 
transgenic mice, at the symptomatic and late stages of the disease (Lo Coco et al., 2007). By contrast, 
we observed a reduction of HMGB1 levels when microglia was added before and after MNs have 
acquired signals of injury (7 DIV). A possible reason may be the advanced stage MNs injury in this 
case, which led to the release of HMGB1. In fact, Lo Coco and colleagues (2007) observed a 
reduction of HMGB1 immunoreactivity in degenerating neurons, with the progression of the disease, 
which reflects an extracellular release of this protein. Moreover, HMGB1 can be used to monitor ALS 
disease progression, as Hwang and colleagues (2013) demonstrated through the study of the serum 
autoantibody against HMGB1 (HMGB1 autoAb), whereupon the level of HMGB1 autoAb significantly 
increased in patients with ALS. 
In the second part of this thesis, we aimed to set-up an organotypical culture model from the 
lumbar SC, in order to study whether cellular cross-talk is impaired in mice carrying the human SOD1 
G93A (TgSOD1-G93A). SC organotypic culture allows preserving an in vivo horizontal architecture, 
keeping MNs in situ, with all the other cells and connections in place. Moreover, the MNs in an 
organotypic culture system can survive for more than three months, being a good model to study the 
effect of long-term treatment with toxic substances on MNs (Li et al., 2008). We have started by 
analyzing some of the parameters evaluated in mixed cultures, such as SOD1 accumulation, ATP and 
NO.  
Again, we observed an increase of SOD1 accumulation in TgSOD1-G93A mice, compared 
with SJL-WT mice (control). Puttaparthi et al (2003) demonstrated that the formation of SOD1-positive 
aggregates in TgSOD1-G93A mouse SC tissue involves proteasome mediated proteolysis. In 
contrast, SOD1 aggregates do not form in SC slices from wt mice or transgenic mice overexpressing 
SOD1 wt, following proteasome inhibition. In sum, their results establish that adult mouse SC exhibits 
a relative deficiency in proteasome activity compared with non-CNS tissue that may help explain the 
propensity of SC to form SOD1-positive aggregates. 
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We then tested the ability of LPS in the triggering of inflammatory response in organotypic 
cultures from Tg-SOD1-G93A, through the evaluation of their receptor TLR-4, ATP and NO. 
Regarding NO, no differences were observed between cultures of wt and TgSOD1-G93A mice, either 
with or without incubation with LPS. Extracellular levels of ATP were reduced in TgSOD1-G93A mice, 
and the presence of LPS also promoted ATP reduction both in Wt and TgSOD1-G93A mice. It is 
described in TgSOD1-G93A mice that mitochondrial dysfunction leads to an energy impairment, which 
reflects in a reduction of ATP released by mutated cells (Mattiazzi et al., 2002). LPS is a potent 
stimulator of M1 activation of microglia (Lewis et al., 2012), which have increased expression of P2X 
receptors (Raouf et al., 2007), which binds to ATP and contributes to reduce their presence in 
extracellular media. In addition, we cannot exclude a possible interaction between LPS and the other 
types of cells present in the slice, such as astrocytes, making them potential contributors for the 
reduction of extracellular ATP levels. 
Finally, we detect the presence of TLR4, which were slightly reduced upon LPS exposure. We 
were expecting an increase of TLR4 activity, once the presence of LPS activate these receptors. 
However this 95 kDa band detected in our western blot belongs to a non-glycosilated form of TLR4, 
which does not translocate to the membrane surface and, consequently, is not responsible for LPS 
binding. We could not detect the 130 kDa band, responsible for the glycosilated form of TLR4, which 
translocates to the membrane surface and binds LPS (Ohnishi et al., 2003).  
Together, and as schematically represented in Figure IV.1, these results show the success of 
the implementation of mixed cultures as well as organotypical cultures to be used in the study of the 
mechanisms involved in ALS. Regarding the signalling between MNs-microglia, we observed a 
reduction of extracelllar ATP and MMPs and a possible release of HMGB1 from mutated MNs in the 
presence of microglia in cullture with MNs until 7 DIV. It is also suggested that microglia is activated 
and modulates a series of signalling mechanisms reponsable for a reduction of NO release, SOD1 
accumulation and a consequent improvement of mitochondria function in NSC-34/hSOD1G93A cells. 
In addition, the results suggest that slices are in a high degeneration/aging state and the presence of 
LPS contributes to increase mitochondrial dysfunction in organotypical culture model. We then may 
propose that microglia has a positive impact to counteract neuroinflammation and prevent MNs from 
degeneration, reinforcing the use of therapeutic strategies that can restore both the healthy state of 
MNs and glial cells in ALS. 
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Figure IV.1 - Schematic representation of the major findings of this Master Thesis.  (A) Mixed cultures 
evidence a reduction of extracelllar Adenosine Triphosphate (ATP) and metalloproteinases (MMPs) and a 
possible release of high-mobility group protein 1 (HMGB1) from NSC-34/hSOD1G93A cells. This can trigger 
microglia activation, thus promoting a set of signalling mechanisms, provoking a reduction of nitric oxide (NO) 
release, SOD1 accumulation and a consequent improvement of mitochondria function in NSC-34/hSOD1G93A 
cells. (B) Organotypic spinal cord cultures were composed by slices in a high degeneration/aging state 
characterized by reduced production of ATP, which is aggravated by the presence of lipopolysaccharide (LPS). 
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Future perspectives 
 
In our study we found important clues about the role of healthy microglia in improving the 
degeneration of mutated motoneurons (MNs), through the use of an in vitro model of mixed cultures. 
However, further investigations are necessary to clarify the exact mechanism that microglia use to 
improve MNs degenerative state, in respect to the reduction of SOD1 accumulation, 
metalloproteinases (MMPs) activation, extracellular NO and ATP, as well as increase of extracellular 
glutamate and HMGB1 levels. For that, it is necessary to study markers involved in microglia 
activation, such as morphological alterations, phagocytic function and the production and release of 
inflammation-related factors, in order to better understand which phenotype microglia acquire to help 
MNs. Moreover, using these cell lines, it will be interesting to evaluate the reaction of injured MNs in 
the presence of microglia also transfected with human SOD1G93A (or even obtained from transgenic 
mice carrying human mutant SOD1), enabling the comparison in what regards behavior and 
communication established between mutated MNs and healthy or mutated microglia. Indeed, the use 
of cell lines brings an advantage, once they allow to study particular interactions without the influence 
of other cells present in surrounding environment. 
Organotypic SC cultures represent a good working model to study ALS, and allow to study the 
interaction between MNs and all glial cells. They can survive for a long time, allowing to study the 
effect of long-term treatment with toxic or beneficial substances. We find that SOD1 accumulation 
triggers mitochondrial dysfunction, as it was demonstrated through mixed culture. However, further 
investigation on the disrupted mechanisms underlying the disease are necessary to perform in this 
model, including  excitotoxicity, deregulation of endosomal trafficking, endoplasmatic reticulum (ER) 
stress, impaired axonal transport and cell death mechanisms. Moreover, organotypic slice cultures 
also has the advantage of allowing the depletion of microglia from the culture system, by using 
liposomes filled with clodronate, which will be ideal to assess microglia involvement along ALS 
progression. It will be interesting to provide continuity on testing some compounds with 
neuroprotective properties, such as glycoursodeoxycholic acid (GUDCA), which has been previously 
demonstrated in our group, to ameliorate some dysfunctions in differentiated NSC-34/hSOD1G93A. 
Finally, in vivo studies using transgenic mice carrying SOD1G93A will be crucial to get a time 
point of each phase of the disease progression and to find biomarkers that allow to identify each of 
this phase.  
Every effort has been taken for a better understanding of the mechanisms involved in the 
pathogenesis of ALS, in order to find an effective therapeutic approach, able to extend lifetime with 
less physical and psychological pain to the patient. 
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